1  TITLE: A Randomized, Phase II Study Evaluating Concurrent or Sequential Fixed -Dose 
Pembrolizumab in Combination with Cisplatin and Intensity Modulated Radiotherapy 
(IMRT) in Intermediate or High Risk, Previously Untreated, Locally Advanced Head and 
Neck Cancer  
HCC  Study Number:  15-132 
Phase:  Randomized Phase II  
Version:  2.0 
Version  Date:  05/22/2019  
Investigational  Agent:  Pembrolizumab  
Commercial  Agent:  Cisplatin  
Radiation Ther apy:  Intensity Modulated Radiotherapy  (IMRT)  
 
 
SPONSOR -INVESTIGATOR : David Clump  MD 
UPMC Hillman Cancer Center 
[ADDRESS_912277] floor Posner Tower  
Pi[INVESTIGATOR_9109], PA  [ZIP_CODE]  
                                                                 Phone: (412) 623 -6720   (24 hours)  
 
 
CO-CHAIRS : 
Radiation Oncology:  Jonathan J. Beitler,  MD, MBA  (Emory University) 
Medical  Oncology:  Julie E.  Bauman, MD  (University of Arizona) 
Translational  Science:  Robert Ferris,  MD, PhD (UPMC)  
 
BIOSTATISTICIAN : Daniel P. Normolle, PhD 
Email:  [EMAIL_4460]  
 
Source(s)  of Support : [COMPANY_006],  Inc. 
2  STUDY SCHEMA  
 
 
 

3  TABLE OF CONTENTS  
STUDY SCHEMA  ................................ ................................ ................................ ................................ ....... 2 
1. BACKGROUND  & RATIONALE  ................................ ................................ ................................ .. 6 
1.1 Disease  Background  ................................ ................................ ................................ ..................  6 
1.1.1 Carcinogen -Induced HNSCC  ................................ ................................ ................................ ............  6 
1.1.2 HPV -Associated HNSCC  ................................ ................................ ................................ .................  6 
1.2 Pembrolizumab  ................................ ................................ ................................ ..........................  6 
1.2.1 Background  ................................ ................................ ................................ ................................ ....... 7 
1.2.2 Rationale for  Dose Selection/Regimen/Modification  ................................ ................................ ....... 8 
1.3 Other Protocol -Specified Drug(s)  Background: Cisplatin  ................................ .........................  9 
1.4 Study  Rationale  ................................ ................................ ................................ ..........................  9 
1.4.1 PD-1 in HNSCC  ................................ ................................ ................................ ................................  9 
1.4.2 PD-1 and  Radiation  ................................ ................................ ................................ .........................  10 
1.5 Correlative  Studies Background  ................................ ................................ ..............................  10 
2. STUDY  OBJECTIVES  ................................ ................................ ................................ ..................  11 
2.1 Primary  ................................ ................................ ................................ ................................ .... 11 
2.2 Secondary  ................................ ................................ ................................ ................................  11 
3. PATIENT SELECTION  ................................ ................................ ................................ ................  11 
3.1 Inclusion  Criteria  ................................ ................................ ................................ .....................  11 
3.2 Exclusion  Criteria  ................................ ................................ ................................ ....................  13 
4. PATIENT REGISTRATION/RANDOMIZATION  ................................ ................................ ...... 15 
5. TREATMENT PLAN  ................................ ................................ ................................ ....................  16 
5.1 Study Drug  Administration:  Pembrolizumab  ................................ ................................ ..........  16 
5.1.1 Route  of Administration  ................................ ................................ ................................ .................  16 
5.1.2 Doses to  be Administered  ................................ ................................ ................................ ...............  16 
5.1.3 Dosing  Schedule  ................................ ................................ ................................ .............................  17 
5.1.4 Order of  Administration  ................................ ................................ ................................ ..................  17 
5.1.5 Prohibited Concomitant  Medicati ons ................................ ................................ ..............................  17 
5.2 Drug Administration  – Cisplatin  ................................ ................................ .............................  17 
5.2.1 Route  of Administration  ................................ ................................ ................................ .................  17 
5.2.2 Doses to  be Administered  ................................ ................................ ................................ ...............  18 
5.2.3 Dosing  Schedule  ................................ ................................ ................................ .............................  18 
5.2.4 Concomitant Medications during  Cisplatin  Infusion  ................................ ................................ ...... 18 
5.3 Dose  Modifications  ................................ ................................ ................................ ..................  18 
5.3.1 Pembrolizumab Dose Modifications  ................................ ................................ ...............................  18 
5.3.2 Cisplatin  Dose Modifica tions ................................ ................................ ................................ ..........  23 
5.4 Intensity Modulated  Radiotherapy  (IMRT)  ................................ ................................ .............  25 
5.4.1 Dose  specifications  ................................ ................................ ................................ .........................  25 
5.4.2 Immobilization  and Simulation  ................................ ................................ ................................ ....... 25 
5.4.3 Target  Delineation  ................................ ................................ ................................ ..........................  26 
5.4.4 Treatment Planning  and Delivery  ................................ ................................ ................................ ... 27 
5.4.5 Image Guidance for IGRT When Using  Reduced  Margins  ................................ ............................  27 
5.4.6 Definition of Normal Tissues/Organs at  Risk (OARs) ................................ ................................ .... 29 
5.4.7 Management of the Low Neck/Supraclavicular Region (Match versus  No Match)  ........................  30 
5.4.8 Dose  Prescription  ................................ ................................ ................................ ............................  30 
5.4.9 Planning Priorities  and Goals  ................................ ................................ ................................ ..........  32 
5.4.10  Critical Structures  ................................ ................................ ................................ ...........................  32 
5.4.11  Image -Guided Radiotherapy  ................................ ................................ ................................ ...........  33 
5.4.12  Radiation Therapy  Treatment  Interruptions  ................................ ................................ ....................  34 
5.4.13  Radiation Therapy  Adverse Events  ................................ ................................ ................................ . 34 
5.5 Duration of Treatment  and Follow -up ................................ ................................ .....................  34 
4 
 5.6 Patient  Discontinuation  ................................ ................................ ................................ ............  35 
5.7 Dose Limiting  Toxicity  (DLT)  ................................ ................................ ................................  35 
5.7.1 DLT ................................ ................................ ................................ ................................ .................  35 
6. RESPONSE  ASSESSMENT  ................................ ................................ ................................ .........  36 
6.1 Solid Tumor Response Criteria (modified RECIST Criteria  version  1.1) ...............................  37 
6.1.1 Malignant  Disease  Evaluation ................................ ................................ ................................ .........  37 
6.1.2 Definitions of  a Response  ................................ ................................ ................................ ...............  38 
6.1.3 Evaluation of Patient's Best  Overall  Response  ................................ ................................ ................  [ADDRESS_912278] and MRI  ................................ ................................ ................................ ................................ .... 41 
6.2.2 Clinical  Examination  ................................ ................................ ................................ ......................  41 
6.2.3 Cytology  and Histology  ................................ ................................ ................................ ..................  41 
6.2.4 FDG -PET Scan  ................................ ................................ ................................ ...............................  41 
7. DRUG  INFORMATION  ................................ ................................ ................................ ................  43 
7.1 Pembrolizumab  ................................ ................................ ................................ ........................  43 
7.1.1 Study  Drug  Materials  ................................ ................................ ................................ ......................  43 
7.1.2 Pembrolizum ab Study  Drug  Storage  ................................ ................................ ...............................  44 
7.2 Cisplatin  ................................ ................................ ................................ ................................ ... 44 
8. CLINICAL AND  LABORATORY  EVALUATIONS  ................................ ................................ .. 45 
8.1 Pre-Registration  Evaluations  ................................ ................................ ................................ ... 45 
8.1.1 Required  Pre-Registration  Evaluations  ................................ ................................ ......................  45 
8.1.2 Required  Pre-Treatment  Evaluations  ................................ ................................ .........................  46 
8.1.3 Recommended  Pre-Treatment  Evaluations  ................................ ................................ ................  46 
8.2 Evaluations  during  treatment  ................................ ................................ ................................ ... 47 
8.2.1 Arm 1 (Cisplatin -IMRT followed by  [CONTACT_675056])  ................................ ..................  47 
8.2.2 Arm 2 (Concurrent pembrolizumab, cisplatin  and IMRT)  ................................ ..............................  [ADDRESS_912279]-treatment  Evaluations  ................................ ................................ ................................ ...... 51 
8.3.1 Response  Assessment  ................................ ................................ ................................ .....................  51 
8.3.2 End of Treatment  Visit(s)  
8.3.3 Surgical  Consolidation  ................................ ................................ ................................ ....................  52 
8.4 Long Term  Follow Up  ................................ ................................ ................................ .............  53 
9. BIOMARKER, CORRELATIVE, OR  SPECIAL  STUDIES  ................................ ........................  54 
9.1 Biomarker sampling  schedule  ................................ ................................ ................................ .. 54 
9.2 Research  biopsies ................................ ................................ ................................ .....................  55 
9.2.1 Research  Biopsy  Methodology  ................................ ................................ ................................ ....... 56 
9.2.2 Sample Prepara tion and  Shipment  Instructions  ................................ ................................ ...............  56 
9.3 Research  Blood  ................................ ................................ ................................ ........................  58 
9.4 Correlative  Science  Studies  ................................ ................................ ................................ ..... 62 
9.4.1 Tumor  PD-L1 Expression  ................................ ................................ ................................ ...............  62 
9.4.2 Tumor Antigen (EGFR, p5 3, E6,  E7) Seroreactivity  ................................ ................................ ...... 63 
9.4.3 Peripheral Blood CD69/137+ or ICOS+ Activated  T cells ................................ .............................  63 
9.4.4 Tumor Cell Immune Escape, Extent of Tumor Infiltrating Lymphocytes (“Immunoscore”), and  
Activating/Suppressive  Ligands ................................ ................................ ................................ ...... [ADDRESS_912280]  ................................ ................................ ................................ ...............  74 
12.4.3  Evaluating  Adverse  Events  ................................ ................................ ................................ .............  75 
12.4.4  Sponsor  Responsibility  for Reporting Adverse  Events  ...............  Error!  Bookmark  not defined. [ADDRESS_912281]  (IRB)  approval  ................................ ................................ ....................  [ADDRESS_912282]  ................................ ................................ ................................ ............  81 
15.2 Packaging and  Labeling  Information  ................................ ................................ .......................  81 
15.3 Clinical  Supplies  Disclosure  ................................ ................................ ................................ .... 81 
15.4 Storage and  Handling  Requirements  ................................ ................................ .......................  81 
15.5 Returns  and Reconciliation  ................................ ................................ ................................ ...... 81 
16. APPENDICES  ................................ ................................ ................................ ................................  82 
Appendix A: Tobacco Use  Assessment  Form ................................ ................................ ..........................  82 
Appendix B: Performance  Status  Criteria  ................................ ................................ ..............................  84 
Appendix D:  CTCAE  v.4.0  ................................ ................................ ................................ .......................  91 
Appendix E: Medwatch  Form 3500A  ................................ ................................ ................................ ...... 92 
17. REFERENCES  ................................ ................................ ................................ ...............................  93 
6  1. BACKGROUND & RATIONALE  
1.1 Disease  Background  
Head and neck squamous cell carcinoma (HNSCC) is the most common cancer arising in the upper 
aerodigestive tract. HNSCC is the sixth leading cancer worldwide with 600,000 cases annually .1 Despi[INVESTIGATOR_675018], 5 -year overall survival (OS) is 40 -60%, and has increased only 
incrementally in the past three decades .[ADDRESS_912283] of care for nonsurgical management of 
previously untreated locally advanced (PULA) HNSCC is concurre nt cisplatin -radiotherapy (RT), which 
improved overall survival (OS), progression -free survival (PFS), and locoregional control (LRC) compared 
with RT alone in the landmark Intergroup 0126 trial .3,4 Although LRC and OS are improved with concurrent 
cisplatin -RT, a meta -analysis indicated disappointing local and distant failure rates of 50% and 15% 
respectively, and an absolute survival benefit of only 6.5% compared to conventionally fractionated  RT 
alone .[ADDRESS_912284] poor OS, PFS and L RC. In RTOG 
[ZIP_CODE] patients with human papi[INVESTIGATOR_28597] (HPV)( -) tumors had an absolute 25.1% reduction in OS at 3 
years (57.1% vs. 82.4%) vs. patients with HPV(+) tumors, with similar reductions in PFS and LRC. Poor 
outcomes p ersist despi[INVESTIGATOR_675019] ,7 multi -drug induction ,8 or EGFR -targeted 
monoclonal antibodies (mAb) .9  For HPV( -) patients, new inte nsification approaches are a major unmet 
need.  
1.1.2 HPV -Associated  HNSCC  
HPV(+) HNSCC is rapi[INVESTIGATOR_560911] .[ADDRESS_912285] HPV(+) tumors. HPV status and pack -years of  tobacco exposure are the major determinants of 
OS in HNSCC, followed by [CONTACT_675057] .6 Based upon HPV status, pack -years and nodal stage, patients with 
HNSCC can be classified patients into three risk groups having low, inte rmediate, or high risk of death. This 
clinical risk classification has framed national clinical trial priorities in PULA HNSCC. Specifically, de - 
intensification strategies are being tested in patients with low -risk HPV(+) HNSCC whereas intensification 
strategies are the major unmet need for high -risk HPV( -) and intermediate -risk HPV(+) disease .11,12 
1.2 Pembrolizumab  
Pembrolizumab (formerly MK -3475) is a potent and highly selective humanized monoclonal antibody 
(mAb) of the IgG4/kappa isotype designed to directly block the interaction between programmed cell death 
protein 1 (PD -1) and its ligands, PD -L1 and PD -L2. KeytrudaTM (Pembrolizumab) has recently been 
approved in the United Stated for t he treatment of patients with unresectable or metastatic melanoma and 
disease progression following ipi[INVESTIGATOR_77972], if BRAF V600 mutation positive, a BRAF inhibitor.  
 
Pembrolizumab was studied in a Phase Ib expansion cohort in patients with recurrent/metas tatic HNSCC .13 
Preliminary clinical data were promising. Half of patients had a decrease in tumor burden and 20% met 
criteria for RECIST response, which was equivalently distributed between HPV(+) and HPV( -) patients.  
Striki ng activity in a heavily pre -treated HNSCC population, coupled to mechanistic insights regarding the 
importance of PD -[ADDRESS_912286] igator Brochure (IB) for descriptions of all preclinical and clinical 
available data.  
1.2.[ADDRESS_912287]  immune  surveillance  in controlling  outgrowth  of neoplastic  transformation  has been 
known for decades .14 Accumulating evidence shows a correlation between tumor -infiltrating lymphocytes 
(TILs) in cancer tissue and favorable prognosis in various malignancies .15-19 In particular, the presence of 
CD8+ T -cells and the ratio of C D8+ effector T -cells/FoxP3+ regulatory T -cells seems to correlate with 
improved prognosis and long -term survival in many solid  tumors.  
 
The PD-[ADDRESS_912288]  hijacked  by [CONTACT_675058].  The 
normal function of PD -1, expressed on the cell surface of activated T -cells under healthy conditions, is to 
down -modulate unwanted or excessive immune responses, including autoimmune reactions. PD -1 (encoded 
by [CONTACT_13228]1) is an Ig superfamily member related to CD28 and CTLA -4 which has been shown to 
negatively  regulate  antigen  receptor  signaling  upon  engagement  of its ligands  (PD-L1 and/or  PD-L2).20,21 The 
structure of murine PD -1 has been resolv ed.22 PD-1 and family members are type I transmembrane 
glycoproteins containing an Ig Variable -type (V -type) domain responsible for ligand binding and a 
cytoplasmic tail which is responsible for the binding of signaling mole cules. The cytoplasmic tail of PD -1 
contains  2 tyrosine -based  signaling  motifs,  an immunoreceptor  tyrosine -based  inhibition  motif  (ITIM)  and an 
immunoreceptor  tyrosine -based  switch  motif  (ITSM).  Following  T-cell stimulation,  PD-[ADDRESS_912289] from that of CTLA -4 as both molecules regulate an overlappi[INVESTIGATOR_209810].26,27 PD- 
1 was shown  to be expressed  on activated  lymphocytes  including  peripheral  CD4+  and CD8+  T-cells,  B-cells, 
T regs and Natural  Killer  cells.28,29 Expression  has also been  shown  during  thymic  development  on CD4 -CD8 - 
(double negative) T -cells as well as subsets of macrophages and dendritic cells.30 The ligands for PD -1 (PD - 
L1 and PD -L2) are constitutively expressed or can be indu ced in a variety of cell types, including non- 
hematopoietic tissues as well as in various tumors26,31-[ADDRESS_912290] 
notably on vascular endothelium, whereas PD -L2 protein is only detectably expressed on antigen -presenting 
cells found in lymphoid tissue or chronic inflammatory environments. PD -L2 is thought to control immune 
T-cell activation in  lymphoid organs, whereas PD -L1 serves to dampen unwarranted T -cell function in 
peripheral tissues .26 Although healthy organs express little (if any) PD -L1, a variety of cancers were 
demonstrated to express abundant levels of this T -cell inhibitor. PD -1 has been suggested to regulate tumor - 
specific T -cell expansion in subjects with melanoma (MEL) .34 This suggests that the PD -1/PD -L1 pathway 
plays a critical role in tumor immune evasion and sh ould be considered as an attractive target for therapeutic 
intervention.  
8  1.2.2 Rationale for Dose  Selection/Regimen/Modification  
An open -label Phase I trial (Protocol 001) was conducted to evaluate the safety and clinical activity of single 
agent p embrolizumab. The dose escalation portion of this trial evaluated three dose levels, 1 mg/kg, 3 
mg/kg, and 10 mg/kg, administered every 2 weeks (Q2W) in subjects with advanced solid tumors. All three 
dose levels were well tolerated, and no dose -limiting to xicities were observed. This first in human study of 
pembrolizumab showed evidence of target engagement and objective evidence of tumor size reduction at all 
dose levels (1 mg/kg, 3 mg/kg and 10 mg/kg Q2W). No MTD has been identified to date. 10.0 mg/kg Q2 W, 
the highest dose tested in PN001, will be the dose and schedule utilized in Cohorts A, B, C and D of this 
protocol to test for initial tumor activity. Recent data from other clinical studies within the pembrolizumab 
program has shown that a lower dose o f pembrolizumab and a less frequent schedule may be sufficient for 
target engagement and clinical  activity.  
 
PK data analysis of pembrolizumab administered Q2W and Q3W showed slow systemic clearance, limited 
volume of distribution, and a long half -life (re fer to IB). Pharmacodynamic data (IL -2 release assay) 
suggested that peripheral target engagement is durable (>21 days). This early PK and pharmacodynamic 
data provides scientific rationale for testing a Q2W and Q3W dosing schedule.  
 
A population pharmacok inetic analysis has been performed using serum concentration time data from [ADDRESS_912291] a 
wide therapeutic  range based on the melanoma indication. The differences in exposure for a 200 mg fixed 
dose regimen relative to a 2 mg/kg Q3W body weight -based regimen are anticipated to remain well within 
the established exposure margins of 0.5 – 5.0 for pembrolizumab i n the melanoma indication. The exposure 
margins are based on the notion of similar efficacy and safety in melanoma at 10 mg/kg Q3W vs. the 
proposed dose regimen of 2 mg/kg Q3W (i.e. 5 -fold higher dose and exposure). The population PK 
evaluation revealed th at there was no significant impact of tumor burden on exposure. In addition, exposure 
was similar between the NSCLC and melanoma indications. Therefore, there are no anticipated changes in 
exposure between different indication settings.  
 
The rationale for further exploration of 2 mg/kg and comparable doses of pembrolizumab in solid tumors is 
based on: 1) similar efficacy and safety of pembrolizumab when dosed at either 2 mg/kg or 10 mg/kg Q3W 
in melanoma patients; 2) the flat exposure -response relationships  of pembrolizumab for both efficacy and 
safety  in the dose ranges  of 2 mg/kg  Q3W  to 10 mg/kg  Q3W;  3) the lack of effect  of tumor  burden  or indication 
on distribution behavior of pembrolizumab (as assessed by [CONTACT_78013]) and 4) the assumption 
that the dynamics of pembrolizumab target engagement will not vary meaningfully with tumor  type.  
 
The choice of the 200 mg Q3W as an appropriate dose for the switch to fixed dosing is based on simulations 
performed using the population PK model of pembrolizumab showing that the fixed dose of 200 mg every 3 
weeks  will provide  exposures  that 1) are optimally  consistent  with those  obtained  with the 2 mg/kg  dose every 
3 weeks;  2) will maintain  individual  patient  exposures  in the exposure  range  establish ed in melanoma  as 
9  associated with maximal efficacy response and 3) will maintain individual patients exposure in the exposure 
range established in melanoma that are well tolerated and safe.  
 
A fixed dose regimen will simplify the dosing regimen to be more convenient for physicians and to reduce 
potential for dosing errors. A fixed dosing scheme will also reduce complexity in the logistical chain at 
treatment facilities and reduce wastage.  
 
1.3 Other Protocol -Specified Drug(s) Background:  Cisp latin  
In PULA HNSCC, where cancer involves regional cervical lymph nodes, the cornerstone chemotherapeutic 
in the definitive radiotherapy setting has been cisplatin.4,35,[ADDRESS_912292] of care for non -operative management as published in  national 
guidelines .37 
Cisplatin [ cis-diamminedichloroplatinum(II)] reacts with DNA to form single base adducts, intrastrand 
crosslinks between 2 bases, and the uniquely lethal interstrand crosslink (ICL).38 The considerable toxicities 
of cisplatin include nausea, hearing loss, nephrotoxicity, myelosuppression, and exacerbation of radiation 
effects such as mucositis and dysphagia .4,39,40 
In Intergroup trial 0126, as well as the adjuvant high risk trials RTOG 95 -01 and EORTC [ZIP_CODE], cisplatin 
was administered at 100 mg/m2every 3 weeks for a total of three doses. High dose bolus cisplatin, as dosed 
in these studies, is clearly associated with greater ototoxicity, nephrotoxicity, and emetogenicity compared 
to daily or weekly cisplatin schedules.41-44 Moreover, compliance with three cycles of high dose cisplatin is 
limited; only 64 -70% of patients completed three cycles in these studies. Recognition of the importance of 
the cumulative dose of cisplatin, greater than or equal to 200 mg/m2, rather than the dosing schedule per se , 
has resulted in increasing preference for weekly  dosing schedules .4,42-45 The RTOG now accepts cisplatin 40 
mg/m2/week concurrent with radiation as the reference standard of care for the adjuvant management of 
high risk HNSCC (RTOG 1216).  
This protocol will use a cisplatin -IMRT backbone consisting of concurrent weekly cisplatin for a total of 7 
doses, rather than high -dose bolus cisplatin, in order to facilitate treatment intensification with 
pembrolizumab. The starting cohort will utilize 40 mg/m2; however if the fixed dose of pembrolizumab 
cannot be added to cisplatin -IMRT without dose -limiting toxicity, then the cisplatin dose will be de - 
escalated to 30 mg/m2 which still results in a cumulative dose of 210 mg/m2. 
1.4 Study Rationale  
1.4.1 PD-1 in HNSCC  
Immunotherapy may be the “fourth modality” in HNSCC, long recognized as an immunosuppressive 
disease. Patients display tumor -permissive cytokine profiles, defective antigen presenting cells (APC), and 
quantitative and qualitative T lymphocyte deficie ncies .46-56 HNSCC tumor -infiltrating lymphocytes (TILs) 
are characterized by [CONTACT_675059] -inhibitory receptors CTLA -4 and PD -1, so -called “immune 
checkpoints.”54,57 Following activation of the T cell receptor (TCR), PD -1 is expressed by [CONTACT_675060] T lymphocytes (CTLs), natural killer cells and dendritic cells. The PD -1 ligands,  
10  PD-L1 and PD -L2, are express ed broadly on non -hematopoietic tissue in response to IFN -γ; PD -[ADDRESS_912293] mechanisms, which could 
be synergistic with immunotherapy: 1) RT -induced tumor cell death releases tumor antigens (TA) for 
processing and presentation by [CONTACT_85804]; 2) RT upregulates chemokines within the tumor microenvironment 
(TME), recruiting TILs and 3) non -lethal RT modulates the tumor phenotype, increasing expression of TA 
and MHC, rendering it more vulnerable to CTL killing .61 However, RT also induces local immune 
suppression by [CONTACT_598387] -L1 on both tumor and myeloid -derived suppressor cells (MDSC), 
reducing the adaptive response and theoretically facilitating future relapse. In two preclinical models, 
concurrent PD -L1 blockade and RT were synergistic in controlling tumor growth, and generated prolonged 
protective T cell immunity as demonstrated by [CONTACT_675061] .62 
2. STUDY  OBJECTIVES  
2.1 Primary  
To evaluate two schedules of fixe d-dose pembrolizumab (concurrent vs. sequential) added to 
standard, concurrent cisplatin -IMRT in patients with PULA HNSCC, in order to 
recommend  the schedule to be tested in a subsequent definitive, randomized study.  
 (please see Section 9.2 for Statistical Methods).  
2.2 Secondary  
Secondary objectives for this study include:  
• To evaluate the toxicity of two sequences of the combination of pembrolizumab  and 
concurrent cisplatin -IMRT in patients with PULA  HNSCC.  
 
3. PATIENT  SELECTION  
3.[ADDRESS_912294] meet all of the following inclusion criteria to be enrolled in the study:  
• Patients must have histologically -confirmed head and neck squamous cell carcinoma with no 
evidence of distant metastasis. The primary site may be the oral cavity, oroph arynx, larynx, or 
hypopharynx. Patients with squamous cell carcinoma of unknown primary, metastatic to cervical 
lymph nodes, are permitted to  enroll.  
• Patients must have high risk or intermediate risk disease, defined below. Staging evaluation should 
be det ermined by [CONTACT_675062], 7th edition.  
o High risk patient must meet one of the following  criteria:  
• Surgically unresectable oral cavity. Patients who are technically resectable but 
refuse surgery due to morbidity (eg. total glossectomy) are also eligible. Medically 
inoperable patients are not  eligible.  
• Larynx: T4 any N; T2 -3 and ≥  N2a.  
11  • Hypopharynx: T1 -2N1-3 or T3-4N0-3. 
• Oropharynx: p16( -) AND T3 -4 or ≥ N2a.  
• Unknown primary: p16( -) AND ≥ N2a.  
[ADDRESS_912295] meet one of the following  criteria:  
• Oropharynx: p16(+) AND one of the  following  
• T3 or ≥ N2a AND ≥ 10 pack -years tobacco exposure (see Tobacco 
Assessment Form, Appendix A) . 
• T4 or N3 disease irrespective of tobacco  exposure.  
• Unknown primary: p16(+) AND one of the  following  
• ≥ N2a AND ≥ 10 pack -years tobacco  exposure.  
• N3 disease irrespective of tobacco  exposure.  
Note: for patients with oropharyngeal or unknown primary tumors, p16 status must 
be known, and can be performed at the local site. p16 -positive disease is defined as  
≥70% of tumor cells demonstrating diffuse nuclear and cytoplasmic staining by p16 
immunohistochemistry (IHC). A positive test for HPV -16 by [INVESTIGATOR_2993] -situ hybridi zation 
(ISH), if this is the local site preference for assessing HPV status, may substitute for 
p16 IHC testing. p16 staining is not required for non -oropharyngeal sites.  
• Patients must be untreated with curative -intent surgery for current diagnosis of Stag e III, IVa,  or 
IVb disease. Diagnostic biopsy of primary tumor and/or nodal sites is  permitted.  
o Diagnostic simple tonsillectomy is permitted, provided patient has RECIST -measurable nodal 
disease.  
o Patients with a second HNSCC primary tumor are eligible for this study, provided more  than 
[ADDRESS_912296] diagnosis of HNSCC, the original tumor was managed 
with surgery only (no adjuvant chemotherapy or radiotherapy), and has not  recurred.  
• Patients with simultaneous primaries or bilateral tum ors are excluded, with the exception of  patients 
with bilateral tonsil cancers or patients with T1 -2, N0, M0 differentiated thyroid carcinoma 
(resected or management deferred), who are  eligible.  
• No prior systemic (chemotherapy or biologic/molecular targete d therapy) or radiation treatment  for 
head and neck  cancer.  
o Patients may have received chemotherapy or radiation for a previous, curatively treated non - 
HNSCC malignancy, provided at least [ADDRESS_912297] be untreated with radiation above the  clavicles.  
• Patients with a history of curatively -treated non -HNSCC malignancy must be disease -free for at 
least 2 years except for excised and cured: carcinoma -in-situ of breast or cervix; non -melanomatous 
skin cancer; T1 -2, N0, M0 resected diffe rentiated thyroid carcinoma; superficial bladder cancer; T1a 
or T1b prostate cancer comprising < 5% of resected tissue with normal prostate specific antigen 
(PSA) since  resection.  
13  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 -1 (See Appendix  B) 
• Age ≥ 18  
• Patients must have measurable disease according to RECIST 1.1 (See Section  6.1) 
• Patients must demonstrate adequate organ function as defined in; all screening labs should  be 
performed within 14 days of treatment  initiation.  
Table 1. Adequate Organ Function Laboratory Values  
 
System  Laboratory Value  
Hematological   
Absolute neutrophil count (ANC)  ≥1,500 /mm3 
Platelets  ≥100,000 / mm3 
Renal   
 
Serum creatinine OR 
Measured or calculateda creatinine 
clearance  
(GFR can also be used in place of 
creatinine or CrCl)  ≤1.5 X upper limit of normal (ULN) OR 
 
Creatinine clearance ≥60 mL/min (for subject with creatinine 
levels > 1.[ADDRESS_912298]) determined by 24 -hour 
collection or estimated by [CONTACT_3158] -Gault formula:  
 
Calculated  creatinine clearance = [(140 -age) X (actual body 
weight in kg) X (0.85 if female)]/(72 X serum creatinine)  
Hepatic   
 
Serum total bilirubin  ≤ 1.[ADDRESS_912299] bilirubin ≤ ULN for subjects with total bilirubin levels >  
1.[ADDRESS_912300] (SGOT) and ALT (SGPT)  ≤ 2.[ADDRESS_912301]  
Coagulation  
International Normalized Ratio (INR) or 
Prothrombin Time (PT)  
 
Activated Partial Thromboplastin Time 
(aPTT)  ≤1.[ADDRESS_912302] is receiving anticoagulant therapy 
as long as PT or PTT is within therapeutic range of intended use 
of anticoagulants  
≤1.[ADDRESS_912303] is receiving anticoagulant therapy  
as long as PT or PTT is within therapeutic range of intended use 
of anticoagulants  
• Written informed consent must be obtained from all patients prior to study registration. Patients 
should have the ability to understand and the willingness to sign a written informed consent 
document.  
• If a woman of childbearing potential, documentation of negative  pregnancy.  
• Within [ADDRESS_912304] dose (see section 8.1.1).  Sexually active patients must agree to use 
adequate contraceptive measures, while on study and for [ADDRESS_912305] dose of study drug. 
All fertile female subjects (and their partners) must agree to use a highly effective method of 
contraception. Ef fective birth control includes (a) intrauterine device (IUD) plus one barrier method; 
or (b) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and 
spermicides (creams or gels that contain a chemical to kill sperm). Should  a woman become 
pregnant or suspect she is pregnant while in this study, she should inform her treating physician 
immediately.  
3.2 Exclusion Criteria  
Patients meeting any of the following exclusion criteria are not to be enrolled in the study:  
• Nasopharyngeal p rimary  site. 
• Current participation in or previous participation in a study of an investigational agent or using  an 
investigational device within [ADDRESS_912306] dose of study  treatment.  
14  • History of severe allergic or anaphylactic reaction s or hypersensitivity to recombinant proteins or 
excipi[INVESTIGATOR_675020].  
• Distant metastatic disease including CNS or leptomeningeal metastases is not  allowed.  
• History of immunodeficiency or is receiving systemic steroid therapy or any other form  of 
immunosuppressive therapy within [ADDRESS_912307] dose of trial  treatment.  
• Received prior monoclonal antibody (for cancer) within 4 weeks prior to study Day 1 or who has 
not recovered (i.e. ≤ Grade 1 or at baseline) from adverse even ts due to agents administered more 
than 4 weeks  earlier.  
• History of second malignancy within 2 years prior to Study Day 1 (except for excised and cured 
non-melanoma skin cancer, carcinoma in situ of breast or cervix, superficial bladder cancer, or T1a 
or T1b prostate cancer comprising < 5% of resected tissue with normal prostate specific antigen 
(PSA) since  resection).  
• Active autoimmune disease requiring systemic treatment within the past 3 months or a documented 
history of clinically severe autoimmune dis ease, or a syndrome that requires systemic steroids or 
immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy would be an 
exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid 
inject ions would not be excluded from the study. Subjects with known hypothyroidism stable on 
hormone replacement, subclinical hypothyroidism, or Sjogren’s syndrome will not be excluded 
from the  study.  
• Acquired Immune Deficiency Syndrome (AIDS) based upon curren t CDC definition; note: HIV 
testing is not required for entry into this protocol. The need to exclude patients with AIDS from  this 
protocol is necessary because the cisplatin and IMRT involved in this protocol may be significantly 
immunosuppressive. Patien ts with known HIV, CD4 counts ≥ 250/μL, and undetectable viral loads 
who are stable on an antiretroviral regimen may be  included.  
• Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative]  is 
detected).  
• Received a live vacc ine within [ADDRESS_912308] dose of trial  treatment.  
• Received prior therapy with an anti -PD-1, anti -PD-L1, anti -PD-L2, anti -CD137, or anti -Cytotoxic 
T-lymphocyte -associated antigen -4 (CTLA -4) antibody (including ipi[INVESTIGATOR_675021] o r drug specifically targeting T -cell co -stimulation or checkpoint  pathways).  
• Significant pulmonary disease, including pulmonary hypertension, interstitial lung disease, or 
active, non -infectious  pneumonitis.  
• History or current evidence of any other medical  or psychiatric condition, therapy, or laboratory 
abnormality that might confound the results of the trial, interfere with the subject’s participation for 
the full duration of the trial, or is not in the best interest of the subject to participate, in the opi[INVESTIGATOR_675022].  
• Peripheral neuropathy ≥ Grade  2 
• Significant cardiovascular disease,  including:  
o Cardiac failure [LOCATION_001] Heart Association (NYHA) class III or  IV. 
o Myocardial infarction, severe or unstable angina within 6 months prior t o Study Day  1. 
o History of serious arrhythmia (i.e., ventricular tachycardia, or ventricular  fibrillation).  
15  o Ventricular cardiac arrhythmias requiring anti -arrhythmic  medications.  
o Known left ventricular ejection fraction (LVEF) ≤  50%.  
• Significa nt thrombotic or embolic events within 3 months prior to Study Day 1. Significant 
thrombotic or embolic events include but are not limited to stroke or transient ischemic attack 
(TIA). Catheter -related thrombosis is not a cause for exclusion. Diagnosis of deep vein thrombosis 
or pulmonary embolism is allowed if the patient is clinically stable and has completed or is on stable 
anti-coagulation  therapy.  
• Major surgery within 6 weeks prior to Study Day 1 (subjects must have completely recovered  from 
any previous surgery prior to Study Day 1). Biopsy, diagnostic tonsillectomy, airway tumor 
debulking or excisional lymph node biopsy do not constitute major  surgery.  
• Active infection requiring antibiotics or antifungals within [ADDRESS_912309] dose of study  drug.  
• Significant electrolyte imbalance prior to enrollment (note that patients may be supplemented to 
achieve acceptable electrolyte  values):  
o Hypomagnesemia < 1.2 mg/dL or 0.5  mmol/L.  
o Hypokalemia < 3.0  mmol/L.  
• Women must not be pregnant or breastfee ding because chemotherapy and/or pembrolizumab may 
be harmful to the fetus or the nursing infant. Pregnant women are excluded from this study  because 
chemotherapy and/or pembrolizumab have the potential for teratogenic or abortifacient  effects.  
4. PATIENT  REG ISTRATION/RANDOMIZATION  
Note: All patients can be registered following eligibility confirmation by [CONTACT_675063] , Carrie Muniz, RN, BSN:  
[ADDRESS_912310]  
Pi[INVESTIGATOR_9109], PA [ZIP_CODE]  
Phone:  (412)  623-6121  
Fax: (412)  648-6650  
E-mail: [EMAIL_4721]  
 
For questions regarding the eligibility of subjects, please contact [CONTACT_39635], David Clump, MD, at 
(412) 623 -6720.  
Registration will require the following information: 1) your name, telephone and email; 2) protocol name 
[CONTACT_114040]; 3) date treatment begins; 4) subject name; 5) date of birth; 6) subject hospi[INVESTIGATOR_675023]; 7) primary study physician; 8) primary treatment institution; 9) confirmation of eligibilit y; 10) 
copi[INVESTIGATOR_675024] 11) verification that the informed consent was signed.  
Randomization will occur at the UPCI Biostatistics Core once consent and eligibility are verified.  
16  5. TREATMENT  PLAN  
Arm 1 (Table 2) : Pembrolizumab will be initiated 2 weeks after the completion of cisplatin -IMRT (week 9 
of protocol treatment) and administered at the fixed dose of 200 mg IV q 3 weeks (+/ - 3 days) for a total of 
24 weeks (8 doses; 6 months). NOTE: Per discretion of the t reating investigator, the week 9 dose of 
pembrolizumab may be delayed up to 3 weeks for recovery of acute toxicities from chemoradiotherapy. This 
dose would be considered delayed, and all subsequent doses would be administered at a q 3 week interval 
(+/- 3 days) from first pembrolizumab dose.  
Arm 2 (Table 3) : Pembrolizumab will be initiated 1 week prior to cisplatin -IMRT (the “window”) at the 
dose of 200 mg IV q 3 weeks (+/ - 3 days). Pembrolizumab will be continued concurrently through cisplatin - 
IMRT (week s 3, 6), and continued for a 15 week maintenance period after completion of cisplatin -IMRT for 
a total pembrolizumab treatment period of 24 weeks (8 doses; 6 months). NOTE: Per discretion of the 
treating investigator, the week 9 dose of pembrolizumab may b e delayed up to 3 weeks for recovery of acute 
toxicities from chemoradiotherapy. This dose would be considered delayed, and all subsequent doses would 
be administered at a q 3 week interval (+/ - 3 days) until completion.  
 
 
Table 2. Arm 1 Treatment  Plan  
 
 
ARM 1  Week of Treatment  
 1 2 3 4 5 6 7 9 12 15 18 21 24 25 30 
IMRT  X X X X X X X         
Cisplatin  X X X X X X X         
Pembrolizumab         X X X X X X X X 
 
 
Table 3. Arm 2 Treatment  Plan  
 
 
ARM 2  Week of Treatment  
 -1 1 2 3 4 5 6 7 9 12 15 18 21 
IMRT   X X X X X X X      
Cisplatin   X X X X X X X      
Pembrolizumab  X   X   X  X X X X X 
 
 
5.1 Study Drug Administration: Pembrolizumab  
5.1.1 Route of  Administration  
Pembrolizumab will be administered as an IV infusion.  
5.1.2 Doses to be  Administered  
The dose of pembrolizumab will be 200 mg (fixed dose) IV every 3 weeks (+/ - 3 days), beginning on week 
9 of treatment (Arm 1) or beginning one week (week -1) prior to concurrent cisplatin -IMRT (in Arm 2).  
17  5.1.3 Dosing  Schedule  
Subjects will receive  pembrolizumab once every 3 weeks (+/ - 3 days) in an IV infusion over 30 minutes.  
Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. However, 
given the variability of infusion pumps from site to site, a windo w of -5 minutes and +10 minutes is 
permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).  
 
The Pharmacy Manual contains specific instructions for the preparation of the pembrolizumab infusion fluid 
and administration of infusion solution.  
 
5.1.4 Order of  Administration  
When cisplatin and pembrolizumab are administered on the same day in Arm 2, pembrolizumab should 
follow cisplatin. Pembrolizumab may be given either before or after the radiation therapy fraction that is 
given the same day.  
5.1.5 Prohibited Conco mitant Medications  
Subjects are prohibited from receiving the following therapi[INVESTIGATOR_675025]:  
 
• Colony stimulating factors, including G -CSF, pegylated G -CSF, and erythropoietin  analogs.  
• Immunotherapy not specifie d in this  protocol.  
• Chemotherapy not specified in this  protocol.  
• Radiation not specified in this  protocol.  
• Investigational agents other than  pembrolizumab.  
• Live vaccines within [ADDRESS_912311] dose of trial treatment and while participating in the 
trial. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, 
chicken pox, yellow fever, rabies, BCG, and typhoid (oral) vaccine. Seasonal influenza vaccines for 
injection are generally killed virus vaccines and are allowed; however intranasal influenza vaccines 
(e.g. Flu -Mist®) are live attenuated vaccines, and are not  allowed.  
 
• Glucocorticoids for any purpose other than the following two clinical  situations:  
o To control  cisplatin -related  nausea,  if viewed  as absolutely  necessary  for symptom  control  by 
[CONTACT_675064].  NOTE:  every  effort  will be made  to minimize  glucocorticoid 
administration either as premedication or as prophylaxis/treatment of delayed nausea from 
cisplatin.  
o To modulate  symptom s from  an event  of clinical  interest  of suspected  immunologic  etiology.  
Subjects who, in the assessment of the treating investigator, require the use of any of the aforementioned 
treatments  for clinical  management  should  be removed  from  the trial. Subjects  may receive  other  medications 
that the investigator deems to be medically  necessary.  
 
There are no prohibited therapi[INVESTIGATOR_3927] -Treatment or Follow -up phases of this trial.  
 
5.2 Drug Administration – Cisplatin  
5.2.1 Route of  Administration  
Cisplatin will be  administered as an IV  infusion.  
18  5.2.2 Doses to be  Administered  
The starting dose of cisplatin will be 40 mg/m2 weekly (+/ - 3 days), beginning concurrent with IMRT during 
week 1 of study treatment in both Arms (see Tables 2 and 3). The actual body weight will be used for all 
patients. There should be no dose modifications because of obesity.  
5.2.3 Dosing  Schedule  
Patients will receive cisplatin once weekly as an IV infusion over 60 minutes, for a total of 7 doses. 
Cisplatin should be administered on Monda y, Tuesday, or Wednesday of each treatment week and may be 
given either before or after the radiation therapy fraction that is given on the same day. When cisplatin and 
pembrolizumab are administered on the same day, pembrolizumab should follow cisplatin.  
5.2.4 Concomitant Medications during Cisplatin  Infusion  
[IP_ADDRESS]  Nausea  
Cisplatin, 30 -40 mg/m2, is a moderately emetogenic drug. For acute nausea and vomiting, premedication 
should include a [ADDRESS_912312], such as granisetron 1 mg iv; ondansetron, up to 16 mg iv; or 
palonosetron, 0.25 mg iv. Palonosetron has a longer half -life (40h) than the fir st generation 5HT3 
antagonists. NOTE: The use of a corticosteroid premedication, such as dexamethasone [ADDRESS_912313] when administering weekly cisplatin. In this protocol, omitting 
scheduled corticosteroid premedic ation, due to the immunosuppressive properties, is strongly encouraged on 
both study arms. However, if necessary in the judgment of the treating investigator, a corticosteroid may be 
administered as a premedication for acute nausea/vomiting. Fosaprepi[INVESTIGATOR_675026].  
Breakthrough nausea and vomiting may be managed at the discretion of the treating investigator. Delayed 
nausea and vomiting (greater than 24 hours after chemotherapy administration) may be managed per 
investigator discretion, including use of the following potential nausea regimens: oral metoclopramide 10 
mg qid x 2 -4 days; prochlorperazine 10 mg qid x 2 -4 days; a 5HT3 antagonist (e.g. granisetron, 
ondansetron) may als o be given for up to 3 days (only if palonosetron was not given prior to chemotherapy). 
Aprepi[INVESTIGATOR_675027]. NOTE: Although dexamethasone and other corticosteroids 
are discouraged for delayed cisplatin -induced nausea in this prot ocol, corticosteroids may be used if viewed 
as necessary by [CONTACT_12707] (e.g. 8 mg bid for 2 days, followed by 4 mg bid for 2  days).  
[IP_ADDRESS]  Hydration and Electrolyte  Support  
Patients must receive vigorous hydration and diuresis. Recommendations are to administer cisplatin, 40 
mg/m2, in NS 1000 ml. Additional IV fluid, potassium chloride, and/or magnesium sulfate may be 
administered at the discretion of the medical oncologist. Mannitol may be administered at the discretion of 
the medical oncologist.  
5.3 Dose Modifications  
5.3.1  Pembrolizumab Dose  Modifications  
Retreatment criteria for pembrolizumab and cisplatin are independent (retreatment criteria for cisplatin are 
specified in section 5.3.2 below). There are no dose reductions for pembrolizumab. If the subject meets 
retreatment criteria, the full dose of [ADDRESS_912314] -chemoradiotherapy dose of pembrolizumab may be 
DELAYED up to 3 weeks to allow for recovery from acute toxicities, in acco rdance with the treating 
investigator’s judgment. In the case of such delay, the following three doses of pembrolizumab will then be 
scheduled every 3 weeks (+/ - 3 days) from the first post -chemoradiotherapy dose.  
 
Subjects should receive appropriate suppo rtive care measures as deemed necessary by [CONTACT_124133]. Suggested supportive care measures for the management of adverse events with potential 
immunologic etiology are outlined in Table 4 below and in greater detail below. Where appropriate, these 
guidelines include the use of oral or intravenous treatment with corticosteroids as well as additional anti - 
inflammatory agents if symptoms do not improve with administration of corticosteroids. Note that several 
courses of steroid tapering may be n ecessary as symptoms may worsen when the steroid dose is decreased. 
For each disorder, attempts should be made to rule out other causes such as metastatic disease or bacterial or 
viral infection, which might require additional supportive care. The treatmen t guidelines are intended to be 
applied when the investigator determines the events to be related to pembrolizumab.  
 
Note: if after the evaluation the event is determined not to be related to pembrolizumab, the investigator is 
instructed to follow the Even ts of Clinical Interest (ECI) reporting guidance but does not need to follow the 
treatment guidance (as outlined in the ECI guidance document). Please see section 12.4.2 for ECI reporting 
guidance.  
 
It may be necessary to perform conditional procedures suc h as bronchoscopy, endoscopy, or skin 
photography as part of evaluation of the event. Suggested conditional procedures, as appropriate, can be 
found in the ECI guidance document.  
 
Table 4. Pembrolizumab Dose Modification Guidelines for Drug -Related Adverse Events  
 
 
Toxicity  Hold  
Pembrolizumab  
For NCI 
CTCAE  Grade   
Timing for Restarting Treatment   
Discontinue Pembrolizumab Permanently  
 
Out-of-field Rash 
(skin rash outside 
of the radiation 
field)   
 
3 Toxicity resolves to Grade 0 -1 and 
the patient has tapered off of or  did 
not require systemic 
corticosteroids. (Ongoing 
management with topi[INVESTIGATOR_675028].)   
Toxicity does not resolve within [ADDRESS_912315] 
dose or inability to taper off of corticosteroids  within 
12 weeks.  
In-field radiation 
dermatitis (skin 
rash within the 
radiation field) – 
Arm 2   
 
4a Toxicity resolves to Grade 3 or 
less. 
NOTE: systemic and topi[INVESTIGATOR_675029] -field.   
 
Toxicity does not resolve to Grade 3 or better within 
6 weeks of completing IMRT  
 
Diarrhea/Colitis  2-[ADDRESS_912316] 
dose.  
3-4 Permanently discontinue  Permanently discontinue  
20   
Toxicity  Hold  
Pembrolizumab 
For NCI  
CTCAE Grade   
Timing for Restarting Treatment   
Discontinue Pembrolizumab Permanently  
 
Type 1 diabetes 
mellitus (if new 
onset) or 
Hyperglycemia   
T1DM or 
3-[ADDRESS_912317] 
dose or inability taper off corticosteroid within 12 
weeks.  
3-4 Permanently discontinue  Permanently discontinue  
Renal Failure or 
Nephritisb – 
Serum/Whole  
Creatinine   
2c  
Toxicity resolves to Grade [ADDRESS_912318] 
dose or inability taper off of corticosteroids within 
12 weeks.  
4 Permanently discontinue  Permanently discontinue  
Note: Permanently discontinue pembrolizumab for any severe or Grade 3 drug -related AE that recurs or any life - 
threatening event.  
a Per investigator discretion, pembrolizumab may be held for grade 3 in -field radiation dermatitis. If pembrolizumab is held for grade 
3 in-field radiation dermatitis, no spe cific grade of resolution is required to restart pembrolizumab; restart would also be per 
investigator discretion.  
bNOTE: Dose modification of cisplatin in the setting of renal insufficiency is addressed separately in Section 5.3.2.  
c NOTE: if event is considered clinically unrelated or unlikely to be related to pembrolizumab , and an alternate clinical explanation 
is likely, probable, or definite in the judgment of the investigator (example, attributable to cisplatin and/or prerenal azo temia in the 
setting of nausea, and responding to hydration), then corticosteroids may be omitted and pembrolizumab may be administered.  
d Patients with intolerable or persistent Grade [ADDRESS_912319] dose of pembrolizumab. Note: Pembrolizumab does not need to be hel d for  
grade 3 dysphagia, grade 3 pain, grade 3 weight loss, or grade 3 fatigue, which are expected toxicities for chemoradiation of  
HNSCC and will be managed aggressively by [CONTACT_675065].  
 
• Pneumonitis : 
o For Grade 2 events , treat with systemic corticosteroids. When symptoms improve to Grade 
1 or less, steroid taper should be started and continued over no less than 4  weeks.  
o For Grade 3 -4 events , immediately treat with intravenous steroids. Administer additional 
anti-inflammatory measures, as  needed.  
o Add prophylactic antibiotics for opportunistic infections in the case of prolonged steroid 
administration.  
21  • Diarrhea/Colitis : 
Subjects should be carefully monitored for signs and symptoms of enterocolitis  (such as diarrhea, 
abdominal pain, blood or mucus in stool, with or without fever) and of bowel perforation (such  as 
peritoneal signs and  ileus).  
 
o All subjects who experience diarrhea/colitis should be advised to drink liberal quantities of 
clear fluids ( or to administer liberal quantities of clear fluids via PEG tube if present). If 
sufficient oral of PEG -tube fluid intake is not feasible, fluid and electrolytes should be 
substituted via IV infusion. For Grade 2 or higher diarrhea, consider GI consultatio n and 
endoscopy to confirm or rule out  colitis.  
o For Grade  2 diarrhea/colitis  that persists  greater  than 3 days,  administer  oral corticosteroids.  
o For Grade 3 or 4 diarrhea/colitis that persists > 1 week, treat with intravenous steroids 
followed by [CONTACT_675066].  
o When symptoms improve to Grade 1 or less, steroid taper should be started and continued 
over no less than 4  weeks.  
 
• Type 1 diabetes mellitus (if new onset, including diabetic ketoacidosis [DKA]) or ≥ Grade 3 
Hyperglycemia, if associated with ketosis (ketonuria) or metabolic acidosis  (DKA):  
 
o For T1DM or Grade 3 – 4 Hyperglycemia:  
▪ Insulin replacement therapy is recommended for Type I diabetes mellitus and for 
Grade 3 -4 hyperglycemia associated with metabolic acidosis or  ketonuria.  
▪ Evaluate patients with serum glucose and a metabolic panel, urine ketones, 
glycosylated hemoglobin, and  C-peptide.  
 
• Hypophysitis : 
 
o For Grade 2 events, treat with corticosteroids. When symptoms improve to Grade 1 or less, 
steroid taper should be started and continued over no less than 4 weeks. Replacement of 
appropriate hormones may be required as the steroid dose is  tapered.  
o For Grade 3 -4 events, treat with an initial dose of IV corticosteroids followed by [CONTACT_79918]. When symptoms improve to Grade  1 or less, steroid taper should be started 
and continued  over no less than 4 weeks.  NOTE:  Replacement  of appropriate  hormones  may 
be required as the steroid dose is  tapered.  
 
• Hyperthyroidism or  Hypothyroidism : 
Thyroid disorders can occur at any time during treatment with pembrolizumab. Of note, patients 
with HNSCC undergoing cisplatin -IMRT may experience subclinical mild hyperthyroidism or 
euthyroid sick syndrome during IMRT, and commonly develop late hypothyroidism as a 
consequence of radiation dose to the thyroid. Monitor patients for changes in thyroid function (TSH 
and free T4 every 3 weeks on Arms 1 and 2, and as indicated based on clinical evaluation) and for 
clinical signs and symptoms of thyroid disorders. No intervention is required for Grade 1 
hyperthyroidism or hypothyroidism events.  
 
o Grade 2 hyperthyroidism  events:  
▪ In hyperthyroidism, non -selective beta -blockers (e.g. propranolol) are suggested as 
initial  therapy.  
o Grade 3 -4 hyperthyroidism  events:  
▪ Treat  with an initial  dose of IV corticosteroid  followed  by [CONTACT_78019].  When 
symptoms improve to Grade 1 or less, steroid taper should be started and continued 
over no less than 4 weeks.  Replacement  of appropriate  hormones  may be required  as 
the steroid dose is  tapered.  
22  o Grade 2 -4 hypothyroidism  
▪ Hypothyroidism is a common consequence of chemoradiotherapy for HNSCC, and 
is likely permanent. In Grade [ADDRESS_912320] of  care.  
 
• Hepatic : 
 
o For Grade 2 events, monitor liver function tests weekly until returned to baseline  values  
▪ Treat with IV or oral  corticosteroids.  
o For Grade  3-4 events,  hospi[INVESTIGATOR_675030].  Treat  with intravenous  corticosteroids  for 
24 to 48 hours. Monitor liver function tests  frequently.  
o When symptoms improve to Grade 1 or less, a steroid taper should be started and continued 
over no less than 4  weeks.  
 
• Renal Failure or  Nephritis : 
Mild to moderate renal insufficiency can occur in the co ntext of cisplatin chemotherapy. Dose 
modification of cisplatin in the setting of renal insufficiency is addressed separately in Section 5.3.2.  
o For Grade  [ADDRESS_912321] possibly  related  to pembrolizumab,  hold pembrolizumab  and treat 
with vigorous  hydration  and oral corticosteroids.  Monitor  renal  function  weekly  until returned 
to baseline  values.  NOTE:  if event  is considered  clinically  unrelated  or unlikely  to be related 
to pembrolizumab , and an alternate clinical explanation is likely, probable, or  definite in the 
judgment of the investigator (example, attributable to cisplatin and/or prerenal azotemia in 
the setting of nausea, and responding to hydration), then corticosteroids may be omitted and 
pembrolizumab may be  administered.  
o For Grade 3 -4 events, hospi[INVESTIGATOR_89648]. Treat with vigorous hydration and IV 
corticosteroids for 24 to 48 hours. Monitor renal function frequently. Consultation with 
nephrology is  recommended.  
o When symptoms improve to Grade 1 or less, steroid taper should be sta rted and continued 
over no less than 4  weeks.  
 
Management of Infusion Reactions : Signs and symptoms usually develop during or shortly after drug 
infusion and generally resolve completely within 24 hours of completion of infusion. Table 5 below shows 
treatment guidelines for subjects who experience an infusion reaction associated with administration of 
pembrolizumab.  
 
 
Table 5. Infusion Reaction Treatment Guidelines  
 
NCI CTCAE Grade  Treatment  Premedication at 
subsequent dosing  
Grade 1  
Mild reaction; infusion 
interruption not  indicated;  
intervention not  indicated  Increase monitoring of vital signs as 
medically indicated until the subject is 
deemed medically stable in the opi[INVESTIGATOR_151733].  None  
Grade 2  
Requires infusion interruption 
but responds promptly to 
symptomatic treatment (e.g., 
antihistamines, NSAIDS, 
narcotics, IV fluids); 
prophylactic medications 
indicated for < =24 hrs  Stop Infusion and monitor 
symptoms.  
Additional appropriate medical therapy 
may include but is not limited to:  
IV fluids 
Antihistamines 
NSAIDS  
Acetaminophen 
Narcotics  
Increase monitoring of vital signs as 
medically indicated until the subject is  Subject may be 
premedicated 1.5h (± 30 
minutes) prior to infusion of 
pembrolizumab with:  
 
Diphenhydramine 50 mg po 
(or equivalent dose of 
antihistamine).  
23  NCI CTCAE Grade  Treatment  Premedication at  
subsequent dosing  
 deemed medically stable in the opi[INVESTIGATOR_8574].  
If symptoms resolve within one hour of 
stoppi[INVESTIGATOR_13056], the infusion 
may be restarted at 50% of the original 
infusion rate (e.g., from 100 mL/hr to 
50 mL/hr). Otherwise dosing will be 
held until symptoms resolve and the 
subject should be premedicated for the 
next scheduled dose.  
Subjects who develop Grade 2 
toxicity despi[INVESTIGATOR_675031].  Acetaminophen 500 -1000 
mg po (or equivalent dose 
of antipyretic).  
Grades 3 or 4  
Grade 3:  
Prolonged (i.e., not rapi[INVESTIGATOR_394230]/or brief 
interruption of infusion); 
recurrence of symptoms 
following initial improvement; 
hospi[INVESTIGATOR_12258] (e.g., 
renal impairment, pulmonary 
infiltrates)  
Grade 4:  
Life-threatening; pressor or 
ventilatory support indicated  Stop Infusion.  
Additional appropriate medical therapy 
may include but is not limited to:  
IV fluids 
Antihistamines 
NSAIDS  
Acetaminophen 
Narcotics 
Oxygen 
Pressors 
Corticosteroids 
Epi[INVESTIGATOR_675032] d until the subject is 
deemed medically stable in the opi[INVESTIGATOR_8574].  
Hospi[INVESTIGATOR_13021]. 
Subject is permanently discontinued 
from further pembrolizumab 
administration.  No subsequent dosing of 
pembrolizumab  
Appropriate resuscitation equipment should be available in the room and a physician readily available 
during the period of drug administration.  
 
 
5.3.2  Cisplatin Dose  Modifications  
There is one level of dose reduction for cisplatin (dose level -1): when dose reduction is required, cisplatin 
will be reduced to 30 mg/m2/week. There is no dose level below 30 mg/m2. Retreatment criteria for 
pembrolizumab and cisplatin are independent. Dose modifications for cisplatin are specified for hematologic 
and non -hematolog ic toxicity in Tables 6 and 7 below.  
24  Table 6. Cisplatin Dose Modifications for Hematologic Toxicity  
 
NCI CTCAE Toxicity 
Grade (CTCAE v. 4)  Cisplatin Dosec,d at Start of Subsequent Cycles of 
Therapy  
Neutropenia   
1 (1500 -1999/mm3) Maintain cisplatin dose level  
2 (1000 -1499/mm3) Maintain cisplatin dose level  
3 (500-999/mm3) Hold cisplatin dose for the week; check CBCD weekly. 
Resume cisplatin at dose level -1 (30 mg/m2/week) when 
neutropenia recovers to Grade 2 or better.  
4 (<500/mm3) Hold  cisplatin dose for the week; check CBCD weekly. 
Resume cisplatin at dose level -1 (30 mg/m2/week) when 
neutropenia recovers to Grade 2 or better.  
Second incident, grade 3 -4 
neutropenia  Hold cisplatin and recheck CBCD weekly. Resume cisplatin 
at 30 mg/m2/week when neutropenia reaches Grade [ADDRESS_912322] treatment. Resume 
cisplatin at 30 mg/m2/week when neutropenia has recovered 
to Grade 2 or better, neutropenic fever has resolved, and  
patient is stable.  
Thrombocytopenia   
1 (75,000/mm3-LLN)  Maintain cisplatin dose level  
2 (50,000 - 74,999/mm3) Hold cisplatin dose for the week; check CBCD weekly. 
Resume cisplatin at dose level -1 (30 mg/m2/week) when  
thrombocytopenia recovers to Grade 1 or better.  
3 (25,000 - 49,999/mm3) Hold cisplatin dose for the week; check CBCD weekly. 
Resume cisplatin at dose level -1 (30 mg/m2/week) when 
thrombocytopenia recovers to Grade 1 or better.  
4 <25,000/mm3) Hold cisplatin dose for the week; check CBCD weekly. 
Resume  cisplatin at dose level -1 (30 mg/m2/week) when 
thrombocytopenia recovers to Grade 1 or better.  
Second incident, grade 2 -4 
thrombocytopenia  Hold cisplatin and recheck CBCD weekly. Resume cisplatin 
at 30 mg/m2/week when thrombocytopenia reaches Grade 1  
or better.  
 
 
 
Table 7. Cisplatin Dose Modifications for Non -hematologic Toxicity  
 
NCI CTCAE Toxicitya 
Grade (CTCAE v. 4)  Cisplatin Doseb 
Renal -serum Creatinine   
≤ Grade 1 (ULN -1.[ADDRESS_912323])  Maintain cisplatin dose level  
Grade 2 (> 1.[ADDRESS_912324])  Hold cisplatin. Check serum creatinine weekly. Resume 
cisplatin at dose level -1 (30 mg/m2/week) when recovered to 
Grade 1 or baseline.  
≥ Grade 3 (>3.[ADDRESS_912325])c Discontinue cisplatin. Per investigator discretion, the patient 
may be changed to carboplatin AU C 2 weekly.  
Fatigue   
Grade 3  Decrease cisplatin to dose level -1 (30 mg/m2/week)  
Nausea/Vomiting   
≤ Grade 2 with maximal 
medical management  Maintain dose level  
≥ Grade 3 with maximal 
medical management  Hold cisplatin until ≤ grade 2, then resume cisplatin at dose 
level -1 (30 mg/m2/week)  
Other non -hematologic 
Toxicitiesd  
25  Neuropathy  
Grade 2  
Grade 3 -4  
Decrease cisplatin to dose level -1 (30 mg/m2/week) 
Discontinue cisplatin. Per investigator discretion, the patient  
may be changed to carboplatin AUC 2 weekly.  
Ototoxicity  
Grade 2  
Grade 3 -4  
Decrease cisplatin to dose level -1 (30 mg/m2/week) 
Discontinue cisplatin  
Other: Mucositis in RT field 
Grade 0 -3 
Grade 4   
Maintain cisplatin dose level  
Hold cisplatin until ≤ grade 3, then resume at dose level -1 
(30 mg/m2/week)  
Rash , in RT field (inclusive 
of radiation dermatitis) 
Grade 2 -3 
Grade 4   
 
Maintain dose leveld 
Hold cisplatin until ≤ grade 3, then resume at dose level -1 
(30 mg/m2/week)  
Rash , out of RT field 
Grade 1 -4  
Maintain cisplatin dose level  
Grade 3 -4/Othere Hold cisplatin until baseline or ≤ grade 1; per investigator 
judgment,may resume cisplatin at dose level -1. Note 
exceptions in footnote.f 
aFor CTCAE Grade ≤ 2 non -hematologic toxicity not described above, attributed  to cisplatin, maintain dose level of 
cisplatin.  
bDose levels are relative to the previous dose. Dose reductions of cisplatin below the –1 dose level will not be allowed. 
For a second incident of non -hematologic toxicity of sufficient severity to requires dose modification, hold cisplatin 
until toxicity resolves to Grade 1 or baseline, then resume at 30 mg/m2/week.  
cIf Grade ≥ [ADDRESS_912326]. Cisplatin may continue at full dose, at the discretion of  the 
treating  physician.  
dPer investigator discretion, cisplatin may be dose -reduced to dose level -1 or held for grade 3 radiation dermatitis. 
e For CTCAE Grade 3 -4 non -hematologic toxicity not described above, attributed to cisplatin, hold cisplatin until 
baseline or ≤ Grade 1. P er investigator judgment, may resume cisplatin at dose level -1. 
f Cisplatin does not need to be held or dose -reduced for grade 3 dysphagia, grade 3 pain, grade 3 weight loss, or grade 3 
fatigue, which are expected toxicities for chemoradiation of HNSCC an d will be managed aggressively by [CONTACT_453803].  
 
If ototoxicity or nephrotoxicity occurs, treatment can be changed to carboplatin with AUC (area under 
curve) of 2 for remainder of concurrent radiotherapy.  
5.4 Intensity Modulated  Radiotherapy  (IMRT)  
5.4.1 Dose  specifications  
IMRT will be delivered in 35 fractions over 7 weeks (five fractions per non -holiday week) in one plan 
(SIB). Concomitant boost using separate IMRT plans is not allowed.  
Missed treatments due to holidays or logistic reasons can be compensated for by [CONTACT_675067], OR treating on the Saturday or Sunday of that week, OR adding to the 
end of  treatment.  
 
5.4.[ADDRESS_912327] an immobilization device (e.g. Aquaplast mask) made prior to treatment planning    
CT scan. Use of an immobilizing mouthpi[INVESTIGATOR_675033], especially those  with 
cancers of the oral cavity and  oropharynx.  
[ADDRESS_912328] be performed with the immobilization device 
and in the treatment position. Slice thickness should be 0.3 cm or thinner.  
 
5.4.3 Targe t Delineation  
The Gross Tumor Volume (GTV) is defined as all known gross disease determined from CT, PET/CT, 
clinical information, endoscopic findings and/or potentially MRI.  
The Clinical Target Volume (CTV) is defined as the GTV plus areas considered to c ontain potential 
microscopic disease, delineated by [CONTACT_1963]. The margin between each GTV and its CTV will 
typi[INVESTIGATOR_175640] a minimum of 0.5 cm except in those areas where the GTV is immediately adjacent to structures 
known to be uninvolved such as bone and adjacent muscle. In this instance, the CTV should be modified to 
exclude structures that serve as a boundary that prevents the natural spread of disease (bone, muscle, etc).  
The Planning Target Volume (PTV) will provide a margin around each CTV  (i.e. both the primary tumor 
and the lymph nodes containing clinical or radiographic evidence of metastases) to compensate for the 
variation of treatment set up and internal organ motion. Studies should be implemented by [CONTACT_675068]; however, an unedited 
expansion of 0.3 - 0.5 cm is recommended.  
In general, the PTV should not go outside of the skin surface; if it does exceed the skin surface, the 
application of bolus material  over this portion of the PTV may be considered if it is judged clinically that the 
skin is at risk but is generally not recommended.  
 
For those institutions that are using daily IGRT for margin reduction, the minimum CTV -to-PTV 
expansion is 3.0 mm (a larg er expansion may be necessary for a target volume subject to significant intra- 
fraction variability, such as the non -immobilized oral tongue). In general, the CTV -to-PTV expansion (with 
IGRT) should not exceed 5  mm. 
 
The primary tumor and involved nodes (CTV1) will typi[INVESTIGATOR_151165] a 0.5 - 1.5 cm expansion of the 
gross tumor volume (GTV) to cover potential local invasion and will be prescribed 2 Gy/fraction, total     
70 Gy (see Section 5.4.8. for details of prescription for  PTV1).  
 
High -risk sub -clinical disease sites, which include possible local subclinical infiltration at the primary 
site (primary site CTV2) and first echelon nodes, which are not clinically or radiographically involved 
(nodal CTV2), should  be expanded by 3 - 5 mm to create PTV2. PTV2 should receive a total dose of 60 
Gy/35 fractions.  
 
Lower -risk targets (PTV3) (such as neck nodal levels which are not first echelon nodes and are not adjacent 
to levels containing grossly involved nodes) will be prescribed 54 Gy/35 fractions  
 
Treatment of the low neck:  see details in Section 5.4.7. If the low neck is treated, the preferred technique is 
to treat with isocentric matching AP or AP -PA fields with larynx block, matched to the IMRT portals just 
above  the arytenoids. The dose  will  be [ADDRESS_912329] be  normalized  such  that  95%  of  the  volume  of  the  PTV1  is  covered  with 
prescription dose of 70 Gy. Additionally: At 1 cc PTV1 volume  on  the  DVH  curve,  the  dose  should 
not be >  110%  of  the prescribed dose. At a volume of 0.03 cc within the PTV1 volume on the DVH 
curve, the dose should not be < 95% of the prescribed dose. For any volume of tissue outside the PTVs that 
has a size of 1 cc, the dose should not be > 74  Gy. 
 
Lymph Node Regions  
 
a. Submental nodes (level IA) : In cases where the floor of mouth, oral tongue, or level IB are  involved.  
 
b. Submandibular nodes ( level IB) : To be covered when the ipsilateral level II has nodal disease of at least  3 
cm or the oral cavity is  involved.  
c. Upper deep jugular (junctional, parapharyngeal) nodes: all cases (at the neck side ipsilateral to the 
primary  tumor).  
d. Subdigastric (jugulodigastric) nodes, midjugular, lower neck, and supraclavicular nodes (levels II through 
IV): all cases, bilaterally; unilateral neck treatment can be considered for well lateralized T1/2 primary 
tumors.  
e. Posterior cervical nodes (level V) : all cases, at the neck side where there is evidence of jugul ar nodal 
metastases.  
f. Medial retropharyngeal nodes: all cases involving the pharyngeal axis (i.e. not required for oral cavity and 
larynx cancers not involving pharyngeal structures) should be contoured from the level of C1 through the 
superior border of th e hyoid  body.  
Critical Normal Structures  
 
The normal tissue volume to be contoured will include the skin surface, brainstem, spi[INVESTIGATOR_1831], mandible, 
glottic larynx, supraglottis, esophagus, trachea, oral cavity, lips and parotid and submandibular salivary 
glands. The PRV (planning risk volume) spin al cord contours will be defined at least 0.[ADDRESS_912330] (i.e. the cord diameter on any given slice will be 1.[ADDRESS_912331] itself ). The normal tissues will be contoured and considered as solid organs . The tissue within the skin 
surface and outside all other critical normal structures and PTVs is designated as unspecified tissue  
5.4.4 Treatment Planning and Delivery  
Megavoltage energy photon beam irradiation is required. Any treatment planning and delivery system 
that has been credentialed for head and neck IMRT for previous RTOG trials is acceptable.  
5.4.5 Image Guidance for IGRT When Using Reduced  Margins  
Daily image guidance of IMRT may be achieved using any one or more of the following techniques:  
• Orthogonal k ilovoltage (KV) images, e.g.  ExacTrac;  
28  • Linear -accelerator mounted kV and MV helical conebeam CT  images;  
• Linear -accelerator mounted MV CT images (e.g.,  Tomotherapy);  
• Other mechanism, after discussion with the Radiation Oncology Co -Chair, Jonat han J. Beitler, 
MD. 
 
The institution’s procedure for registering daily treatment imaging datasets with a reference dataset should 
comply with the following recommendations:  
 
Region -of-Interest (ROI) or “clip box” for fusion should be set to encompass the high dose PTV and 
adjacent spi[INVESTIGATOR_1831]; if the supraclavicular region is a part of the target volume the ROI should extend to the 
C6 level; If the fusion software allows the user to create an  irregular  ROI  (e.g.,  ExacTrac), treatment 
room objects  seen   on  in -room  x -rays  should  be  excluded  from  the registration; manual  (e.g.,  based  
on bony anatomy) and automatic (e.g., based on mutual information) types of registration can be used; the 
result of the fusion must be visually checked for the alig nment of the bony anatomy, such  as vertebral bodies 
and applicable soft tissue structures (e.g., optic nerves and/or optic  chiasm).  
 
Following the registration, the translational and (if the appropriate technology is available) rotational 
corrections shoul d be applied to the treatment couch. If all the variances  are less than 2.5 mm (this 
typi[INVESTIGATOR_537560]), the treatment can proceed without correction 
(however, the physician/team may elect to perform adjustments eve n for a variance < 2.5 mm). If one or 
more corrections are 2.5 -5 mm, adjustment is necessary prior to treatment; however, re -imaging is not 
mandatory. If one or more of the corrections are larger than [ADDRESS_912332] be repeated in addition 
to perfo rming table/positioning adjustments. However, the use of numerous repeat IGRT studies should be 
avoided (see next  section).  
 
Management of Radiation Dose to the Patient from IGRT  
Estimates of patient doses per imaging study for various imaging systems vary  considerably. The doses are 
in the range of 1 mGy for Cyberknife’s and BrainLab’s ExacTrac planar kV - systems. The doses from 
helical MV CT scan on a tomotherapy unit were estimated to be in the range of [ADDRESS_912333] are in the range of 10 cGy for a pelvis study to 6 cGy for a head and neck study. Thus, 
the doses for 3D imaging systems are in the range from 1 to 6 cGy for head  and neck imaging and can 
contribute from 0.5 to 3% to the daily dose of 2.0 Gy. These dose estimates apply to a single imaging 
procedure, and the 2 cGy dose is used as a typi[INVESTIGATOR_675034]. It is import ant to point out that the imaging dose typi[INVESTIGATOR_675035]’s anatomy that 
are outside the high -dose region that is treated therapeutically, and that it  is  sometimes  necessary  to 
repeat the procedure  a  number  of times during, before , or after a single fraction delivery. The imaging 
dose to nearby [CONTACT_675069] (e.g., requiring frequent corrections of more than 5 mm). It i s 
recommended that patients demonstrating severe set up problems during the first week of treatment be 
moved to a treatment with larger  margins.  
29  5.4.6 Definition of Normal Tissues/Organs at Risk (OARs)  
NOTE : Only the parts of the normal tissues/org ans at risk outside the PTVs will be considered 
for dose optimization purposes.  
 
Spi[INVESTIGATOR_35406] : The cord begins at the cranial -cervical junction (i.e. the top of the C1 vertebral body). 
Superior to this is brainstem and inferior to this is cord. The inferior  border of the spi[INVESTIGATOR_675036] T3 -4 (i.e., just below the lowest slice level that has PTV on it). The spi[INVESTIGATOR_675037]. In addition, however, a Planning Risk Volume (PRV) 
spi[INVESTIGATOR_675038]. The PRVcord = cord + 5 mm in each dimension. This is irrespective of 
whether or not IGRT is used.  
 
Brainstem : The inferior most portion of the brainstem is at the cranial -cervical junction where it meets 
the spi[INVESTIGATOR_1831]. For the purposes of th is study, the superior most portion of the brainstem is 
approximately at the level of the top of the posterior clinoid. The brainstem shall be defined based on the 
treatment planning CT scan. In addition, however, a Planning Risk Volume (PRV) brainstem sha ll be 
defined. The PRVbrainstem = brainstem + 3 mm in each dimension.  
 
Lips and Oral Cavity : These should be contoured as 2 separate structures as the goal is to keep the lip 
dose much lower than the oral cavity dose. The definition of lips is self -explanatory. The oral cavity 
will be defined as a  composite  structure  consisting  of  the anter ior ½ to 2/3 of the oral tongue/floor 
of mouth, buccal mucosa, and  palate.  
 
Parotid Glands : Parotid glands will be defined based on the treatment planning CT scan.  
 
OARpharynx : This will be defined as the “uninvolved” posterior pharyngeal wall plus adjacen t 
constrictor muscles. This extends from the superior constrictor region (the inferior pterygoid plates level) 
to the cricopharyngeal inlet (posterior cricoid cartilage level).  
 
Cervical Esophagus : This will be defined as a tubular structure that starts at  the bottom of 
OARpharynx and extends to the thoracic inlet.  
 
Glottic/Supraglottic Larynx (GSL) : This will be defined as a “triangular prism shaped” volume that 
begins just inferior to the hyoid bone and extends to the cricoid cartilage inferiorly and exte nds from the 
anterior commissure to include the arytenoids. This includes the infrahyoid but not suprahyoid epi[INVESTIGATOR_24050].  
 
Mandible : This includes the entire boney structure of the mandible from TMJ through the symphysis.  
 
Unspecified Tissue Outside the Targ ets: This will be defined as tissue located between the skull base and 
thoracic inlet that is not included in either the target volumes or the normal tissues described above.  
 
In cases of weight loss > 10% or significant shrinkage of lymphadenopathy during  therapy, it is 
recommended that the immobilization mask will be adjusted or re -made in order t o preserve  
[ADDRESS_912334] dataset should be used for IGRT image registration when th e patient’s shape changes 
significantly.  
 
5.4.7 Management of the Low Neck/Supraclavicular Region (Match versus No  Match)  
It is recognized that comprehensive head and neck irradiation incorporating IMRT can be done in several 
ways, any of which is permitted for this study. Patient -specific QA measurements are required for all IMRT 
treatments. When a field “match” technique is used for treating the lower neck, patient -specific 
measurements should include a verification of the dose coverage in the gap region for ea ch patient.  
 
1. Match:  The upper cervical lymphatics and primary tumor bed are treated with IMRT. The lower 
cervical lymphatics and supraclavicular region are treated with a single AP (or occasionally APPA for 
larger patients with posterior neck at high risk)  non-IMRT technique. The latter non -IMRT field(s) is 
matched to the upper neck IMRT fields.  This  technique requires comprehe nsive mid-line spi[INVESTIGATOR_675039]. This technique also allows for a simultaneous blocking  of 
portions  of the larynx, hypopharynx, and cervical esophagus in the lower neck fields. Matching 2 IMRT 
plans is  allowed.  
2. No Match:  The entire clinical target volume (CTV) [upper and lower neck and primary tumor bed] is 
irradiated with IMRT. There is no match line between upper and lower portions of the regions at risk. In 
this technique, limiting radiotherapy dose to organs at risk ( OARs), e.g., the cervical esophagus, is 
entirely achieved by [CONTACT_675070].  
 
5.4.8 Dose  Prescription  
Doses to PTVs  
See Sections above for definitions of CTVs and PTVs and their prescribed doses. The goal is for 95% of   
the PTV70  to receive ≥ 2 Gy with a minimum dose (cold spot) of no less than 66.[ADDRESS_912335]:  The PRVcord (as defined in Section 5.3.6.) should not exceed ≤ 50 Gy to any volume in 
excess of 0.03 cc ( approximately 3 mm x 3 mm x 3 mm). In treatment planning, the spi[INVESTIGATOR_537561].  
31  Brainstem : The PRVbrainstem (as defined in Section 5.3.6.) should not exceed 52 Gy to any volume in 
excess of 0.03 cc (approxi mately 3 mm x 3 mm x 3 mm). In treatment planning, the PRVbrainstem 
should be given less priority than the PRVcord but more priority than the other critical structures listed 
below.  
 
Lips:  Reduce the dose as much as possible. The mean dose should be < 20 G y. This may be 
exceeded in oral cavity cancers.  
 
Oral Cavity:  Reduce the dose as much as possible. The mean dose should be < 30 Gy for the non -  
involved oral cavity. Efforts should also be made to avoid hot spots (> 60 Gy) within the non -involved oral 
cavity. 
 
Parotid Glands : In most cases, it will be easier to spare one parotid than the other. The treatment planning 
goal will be for this individual parotid gland to receive a mean dose of < 26 Gy. Taking  into  account  
new data suggesting monotonous impro vement in saliva as dose is reduced, without  a  threshold 
(Dijkema  2010),  the objective  will be to reduce  the 
mean doses to both parotid glands as much as possible.  
 
Contralateral submandibular gland : If contralateral level I is not a target, aim to reduce mean contralateral 
submandibular gland to < 39 Gy.  
 
OARpharynx : Reduce the dose as much as possible. Some recommended (but not mandatory) treatment 
goals include: 1) No more than 33% of the OARpharynx exceeds 50  
Gy; 2) Mean dose < 45 Gy; 3) No more than 15% of the OARpharynx exceeds 60 Gy.  
 
Cervical Esophagus : Reduce the dose as much as possible. Some recommended (but not required) 
treatment goals include: Mean dose < 30 Gy.  
 
Glottic and Supraglottic larynx (GSL) : Reduce the dose as much as possible.  The glottic larynx me a n dose 
is recommended to be < 20 Gy. If whole -neck IMRT is used, under - dosage of PTV2/PTV3 adjacent to the 
glottic larynx will be limited to < 10% receiving  
< 95% prescribed dose (this under -dosage is similar to that caused by [CONTACT_675071]-field IMRT; Webster 2009).  
 
Mandible:  Reduce the dose as much as possible. Hot spots within the mandible should be avoided. It is 
recommended that maximum dose within the mandible be < 66 Gy, except in areas overlappi [INVESTIGATOR_127105].  
 
Unspecified Tissue Outside the Targets : No more than 1cc of unspecified tissue outside the targets can 
receive [ADDRESS_912336]  
2. Brainstem  
3. PTV1  
4. PTV2 (if  applicable)  
5. PTV3 (if  applicable)  
6. a. OARpharynx  
b. Parotid gland contralateral to primary tumor site  
7. a. GSL  
b. Esophagus  
8. a. Lips  
b. Oral Cavity  
9. a. Parotid gland ipsilateral to primary tumor  site 
b. Mandible  
10. Unspecified tissue outside the  targets  
 
5.4.10  Critical  Structures  
Note:  All required structures must be labeled as listed in the table below for digital RT data submission. 
Resubmission of data may be required if labeling of structures does not conform to the standard 
DICOM name [CONTACT_121056].  
 
Table [ADDRESS_912337] Name  [CONTACT_675090] (Gy)  
   
GTV  Primary tumor and involved  [ADDRESS_912338] Echelon nodal regions  60 
  
 
 
PTV60  CTV to PTV expansion should be 
5 
mm minimal margin without  60 
CTV50  Lower risk nodal regions  50 
PTV50  CTV to PTV expansion 
should be 5 mm minimal 
margin without IGRT+  50 
CTV54  Lower risk nodal regions  54 
PTV54  CTV to PTV expansion  
should be 5 mm minimal 
margin without IGRT; [ADDRESS_912339]  ≤ 48 
Spi[INVESTIGATOR_280496]_05  Planning risk Volume of 5 mm  ≤ 50 
BrainStem  Brain Stem  ≤ 50 
BrainStem_03  Planning Risk Volume of 3 mm  ≤ 52 
Parotid  Mean doses to one Parotid  ≤ 26 
OralCavity (excluding PTV’s)  Oral Cavity  Mean dose ≤ 32  
Mandible (excluding PTV’s)  Mandible  D0.03cc < 66  
OARPharynx  Uninvolved posterior pharyngeal 
wall 
plus adjacent constrictor muscles;  Mean dose ≤ 40  
Esophagus_Up  Cervical Esophagus  Mean dose ≤ 30  
Larynx  Glottic/Supraglottic Larynx  Mean dose ≤ 35  
NonPTV_7000  Maximum dose (hot spot > 1cc 
outside the PTVs)  D1cc < 63  
 
 
 
5.4.11  Image -Guided  Radiotherapy  
Daily image guidance of IMRT may be achieved using any one or more of the following techniques:  
• Orthogonal kilovoltage (KV)  images.  
• Linear -accelerator mounted kV and MV cone -beam CT images  (CBCT).  
  
 
5.4.[ADDRESS_912340] treatment interruptions for > 3 weeks will be taken off study. The interruption of 
radiation therapy for grade 4 mucositis / dermatitis / dysphagia is at the discretion of the treating radiation oncologist. 
Treatment breaks, if necessary, ideally should not exceed five treatment days at a time and ten treatment days total. 
Treatment b reaks should be allowed only for resolution of severe acute toxicity and/or for intercurrent illness and not 
for social or logistical reasons. Cisplatin and pembrolizumab will not be administered during radiotherapy treatment 
breaks.  
5.4.13  Radiation Therapy Adve rse Events  
The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events 
(CTCAE), version [ADDRESS_912341] access 
to a copy of the C TCAE, v. 4. A copy of the CTCAE, v. 4 can be downloaded from the CTEP web site 
(http://ctep.cancer.gov ). 
Grade 3 therapy -induced mucositis and/or dysphagia are expected to develop in about one third to one half of  patients. 
Nutritional evaluation prior to the initiation of therapy for a prophylactic gastrostomy (PEG) tube placement is highly 
recommended. Placement of a feeding tube should be recorded on the appropriate case report form, as should use of a 
feeding t ube during and after treatment (e.g., greater than or less than 50% of nutrition by [CONTACT_181616]). Other common 
radiation adverse events include: fatigue, weight loss, regional alopecia, loss of teeth or cavities, xerostomia, 
hoarseness, transient ear discomfort, dysgeusia, increased sensitivity of the skin to hot and cold temperature as well as 
the sun and skin erythema and desquamation within the treatment fields.  
Less common long -term treatment adverse events include: hypothyroidism, loss of hearing, chronic swa llowing 
dysfunction requiring permanent feeding tube, brachial plexopathy, and cervical fibrosis. Much less common radiation 
adverse events include: mandibular osteoradionecrosis (< 5% incidence with attention to dental recommendations), 
and cervical myelo pathy (< 1% with restriction of spi[INVESTIGATOR_181586] ≤ 45 Gy).  
Rare but serious side effects that may develop including fibrotic tissue formation, soft tissue ulceration and/or irritation 
or damage to the skin within the neck that may result in bleeding. Bl indness and the development of secondary (new) 
cancers and tumors is very rare but also possible.  
5.5 Duration of Treatment and  Follow -up 
Complete treatment includes the course of definitive radiotherapy with concurrent chemotherapy and a total of 8 doses 
of pembrolizumab. In the absence of treatment delays due to adverse event(s), treatment may continue until disease 
progression or until one of the following criteria applies:  
• Intercurrent illness that prevents further administration of  treatment,  
• Unacceptable adverse  event(s),  
  
 
• Patient decides to withdraw from the study,  or 
• General or specific changes in the patient's condition render the patient unacceptable for further 
treatment in  the judgment of the investigator.  
 
Patients will be followed for progression and survival every [ADDRESS_912342]. Patients removed from 
study for unacceptable adverse event(s)  will be followed until resolution or stabilization of the adverse event.  
5.6 Patient  Discontinuation  
Subjects who meet the following criteria should be discontinued from study treatment:  
• Inability of subject to comply with study  requirements.  
• The patient elects to withdraw from the study for any  reason.  
• Determination by [CONTACT_86619].  
• Disease progression - patients who undergo surgical consolidation and are found to have residual disease 
are not considered to  have disease  progression.  
 
5.7 Dose Limiting Toxicity (DLT)  
Dose Limiting Toxicity will be continuously monitored in both treatment arms, and is explicitly 
intended for the purposes of safety monitoring of the concurrent combination of pembro lizumab 
and cisplatin -IMRT (Arm 2). As defined, excess DLT is not expected during standard of care 
cisplatin -IMRT. Excess DLT in either arm, however, would trigger the early stoppi[INVESTIGATOR_1877]. Please 
see Section 10.3 for details of the early stoppi[INVESTIGATOR_1877].  
 
5.7.1 DLT  
DLT is defined as the occurrence of a severe adverse event (AE) listed below that is at least possibly 
related to pembrolizumab and occurs within 24 weeks of the initiation of pembrolizumab on either 
treatment arm. AEs will be graded according to N CI CTCAE version 4.0.  
DLT Definition:  
Since autoimmune/inflammatory events may occur at any time during the course of treatment, and may occur with 
evidence of clinical benefit, the following criteria will be used to define DLT:  
  
 
• Any ≥ Grade 4 non -hematologic toxicity  except : 
o Grade 4 in -field radiation dermatitis for which IMRT is held ≤ 1 week (5  fractions).  
o Grade 4 mucositis for which IMRT is held ≤ 1 week (5  fractions).  
o Asymptomatic Grade [ADDRESS_912343] s to Grade  
≤ 2 with replacement therapy.  
• An alanine or aspartate amino transaminase elevation of greater than three times the upper limit of normal 
with concurrent elevation of bilirubin two times the upper limit of normal attributable to pembrolizumab 
should be considered a DLT. Patients meeting this criterion should be permanently discontinued from  
pembrolizumab.  
• Autoimmune toxicity of any grade requiring systemic corticosteroids or other anti -inflammatory that cannot 
be tapered off in less than 12 weeks.  
• Delay in completion of radiation therapy >[ADDRESS_912344] possibly attributed to  pembrolizumab.  
• Grade ≥ 3 neutropenia with fever (oral temperature >  39°C).  
• Grade ≥ [ADDRESS_912345] 12 -14 +/- 2 weeks 
following completion of IMRT. Note, an integrated PET/CT with contrasted diagnostic CT scan is recommended if 
feasible at the participating site; however, on ly a diagnostic CT scan is required. Rare patients may require an MRI for 
tumor measurements, due to allergy to iodinated contrast despi[INVESTIGATOR_250896]. In these patients, MRI of the neck 
should be performed at baseline and at first response  assessment.  
Responses will be coded for:  
• Clinical examination response, primary and  nodes.  
• CT response, primary and nodes (see modified RECIST criteria version 1.1, Section  6.1). 
  
 
• If applicable: Integrated PET/CT response, primary and nodes (see Integrated PET/CT 
response criteria, Section 6.2.4). Solid Tumor Response Criteria (modified RECIST Criteria version  
1.1) 
6.1.[ADDRESS_912346] one measurable lesion.  
All measurements should be recorded in metric notation by [CONTACT_2363] a ruler or calipers. The same method of assessment 
and the same techn ique should be used to characterize each identified lesion at baseline and during follow -up. All 
baseline evaluations should be performed as closely as possible to the beginning of treatment and never more than 
four weeks before registration.  
The term unev aluable in reference to measurability will not be used because it does not provide 
additional meaning or accuracy. At baseline, the primary tumor and pathologic neck lymph nodes 
will be characterized as either measurable or non -measurable.  
[IP_ADDRESS]  Measurable  Disea se 
[IP_ADDRESS].[ADDRESS_912347] one dimension (longest diameter to be recorded) as ≥ 20 mm 
(2.0 cm) with conventional techniques or as ≥ 10 mm (1.0 cm) with spi[INVESTIGATOR_25457].  
[IP_ADDRESS].2  Neck Lymph  Nodes  
Neck lymph nodes are considered pathologic and measurable if short axis ≥ 15 mm.  
Neck lymph nodes are considered pathologic but non -measurable if short axis ≥ 
10 mm but < 15 mm. Neck lymph nodes are considered non -pathologic and 
non-measurable if short axis < 10 mm.  
[IP_ADDRESS] No n-measurable disease  
All other lesions, including small lesions [longest diameter < 20 mm (2.0 cm) with conventional techniques or < 10 
mm (1.0 cm) with spi[INVESTIGATOR_25457]] are truly non -measurable lesions.  
Lesions considered to be truly non -measurable include  the following: bone lesions, leptomeningeal disease, ascites, 
pleural/pericardial effusion,  
  
 
inflammatory breast disease, lymphangitis cutis/pulmonis, abdominal masses that are not confirmed and followed 
by [CONTACT_15218], and cysti c lesions.  
6.1.2 Definitions of a Response  
[IP_ADDRESS]  Target  Lesions  
All measurable lesions, including the primary tumor, and up to a maximum of five neck lymph nodes, should be 
measured at baseline.  
The sum of the longest diameter of the primary tumor, and the short axis diameter of target pathologic lymph nodes, 
will be calculated at baseline and reported as the baseline sum diameter . 
[IP_ADDRESS].1  Complete Response  (CR)  
The disappearance of the primary tumor and the resolution of pathologic neck adenopathy. For the definition of 
radiographic complete response in the neck, the resolution of neck lymph nodes to < 10 mm in short axis diameter with 
non-pathologic appearance is sufficient.  
[IP_ADDRESS].2  Partial Response (PR)  
At leas t a 30% decrease in the sum of target lesion diameters (longest diameter of the primary tumor; short axis 
diameter of the target lymph nodes), taking as reference the baseline sum diameter . 
[IP_ADDRESS].3  Progressive Disease  (PD)  
At least a 20% increase in the sum of tar get lesion diameters (longest diameter of the primary tumor; short axis 
diameter of the target lymph nodes), taking as reference the smallest sum diameter recorded since the baseline sum 
diameter measurements, or the appearance of one or more new lesion(s) . 
[IP_ADDRESS].4  Stable Disease  (SD)  
Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.  
[IP_ADDRESS]  Non-target  Lesions  
All other lesions or sites of disease. Measurements of these lesions are not required, but the presence or 
absence of each sh ould be noted throughout follow -up. 
[IP_ADDRESS].1  Complete Response  (CR)  
The disappearance of all nontarget lesions and normalization of tumor marker levels, if applicable.  
  
 
[IP_ADDRESS].2  Partial Response (PR)/Stable Disease  (SD)  
The persistence of one or more nontarget lesion(s).  
[IP_ADDRESS].3  Progressive Disease  (PD)  
The appearance of one or more new lesion(s) and / or unequivocal progression of existing non target lesions.  
[IP_ADDRESS] Symptomatic Deterioration  
Patients with a global deterioration of health status requiring dis continuation of treatment without objective evidence of 
disease progression at that time should be classified as having symptomatic deterioration.  
6.1.3 Evaluation of Patient's Best Overall Response  
The best overall response is the best response recorded from re gistration until disease progression/recurrence, taking 
as reference for progressive disease the smallest measurements recorded since registration. Table [ADDRESS_912348] once 
after study entry at a minimum interval of eight weeks.  
Table 9. Overall Response for all Possible Combinations of Tumor Response  
Target Lesions  Nontarget Lesions  New Lesions  Overall Response  
CR CR No CR 
CR Incomplete response/SD  No PR 
PR Non-PD No PR 
SD Non-PD No SD 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease  
NOTE: BOTH CLINICAL (by [CONTACT_675072]) AND RADIOGRAPHIC RESPONSE (by [CONTACT_28842]) 
will be recorded. Response in the primary and the neck will be reported separately.  
  
 
[IP_ADDRESS]  First Documentation of  Response  
The time between initiation of therapy and first documentation of PR or CR.  
[IP_ADDRESS]  Confirmation of Response  
To be assigned a status of complete or partial response, changes in tumor measurements must be confirmed by [CONTACT_675073].  
[IP_ADDRESS]  Duration of  Response  
Duration of overall response - the period measured from the time that measurement criteria are met for complete or 
partial response (whichever  status is recorded first) until the first date that recurrent or progressive disease is objectively 
documented, taking as reference the smallest measurements recorded since treatment started.  
[IP_ADDRESS]  Duration of Overall Complete Response  
The period measured from the time measurement criteria are met for complete response until the first date that recurrent 
disease is objectively documented.  
[IP_ADDRESS]  Duration of Stable Disease  
A measurement from registration until the criteria for disease progression is met, taking as refer ence the smallest 
measurements recorded since registration. To be assigned a status of stable disease, measurements must have met the 
stable disease criteria at least once after study entry at a minimum interval of six weeks.  
[IP_ADDRESS]  Survival  
Survival will be meas ured from the date of entry on study.  
[IP_ADDRESS]  Time to Progression and Progression -free survival  
This interval will be measured from the date of entry on the study to the appearance of new metastatic lesions or 
objective tumor progression. Progression -free survival  (PFS) will be calculated from treatment initiation to disease 
progression or death from any cause or last follow up.  
  
 
6.[ADDRESS_912349] and magnetic resonance imaging (MRI) are the best currently available and most reproducible methods for 
measuring target lesions. Conventional CT and MRI should be performed with contiguous cuts of [ADDRESS_912350] -protocol 
endoscopic examination.  
6.2.3 Cytology and  Histology  
Cytologic and histologic techniques can be used to differentiate between complete and partial response in rare cases 
(e.g., after treatment to differentiate residual benign les ions and residual malignant lesions in germ cell tumors). 
Cytologic confirmation of the neoplastic nature of any effusion that appears or worsens during treatment is required 
when the measurable tumor has met response or stable disease criteria.  
Should pri mary site biopsy, primary site salvage, and/or neck dissection be conducted, the pathologic response will be 
recorded.  
6.2.[ADDRESS_912351] -chemoradiotherapy response assessment method would accomplish two goals: 1) accurately detect viable 
residual  disease amenable to surgical consolidation and 2) be prognostic for longer term clinical outcomes including 
PFS. Head and neck clinical examination alone has an accuracy of less than 50% for residual neck nodal disease ,[ADDRESS_912352] -chemoradiotherapy positron emission tomography (PET), performed [ADDRESS_912353] for classification of complete 
response in PULA HNSCC. The negative predictive value (NPV) for determination of residual neck disease,  in 
particular, ranges from 92 -100% .66-69 The University of Pi[INVESTIGATOR_675040]/CT 
scans permit safe deferral of planned neck dissection following chemoradiotherapy. Moreover, a PET scan added to a 
diagnostic contrasted CT is superior to clinical examination or diagnostic CT alone  
  
 
(utilizing RECIST criteria 1.0) with regard to correlation with PFS.[ADDRESS_912354] 1.1 now incorporates 
new guidelines for the measurement of nod al disease, and for determination of CR, a short axis of < [ADDRESS_912355] 1.1 criteria for assessment of residual disease or as a 
predictor of PFS following chemoradiotherapy for PULA HNSCC is not reported.  
To date, the majority of PET/CT literature conducted has been retrospective. The sole prospective study of PET/CT 
versus CT for first response assessment following chemoradiotherapy was performed at MDACC .66 This s tudy found 
that PET/CT was not superior to diagnostic CT alone for the accuracy of response assessment in unselected PULA 
HNSCC patients. However, in high risk patients defined as HPV -negative, non - oropharynx, and/or tobacco -exposed, 
PET/CT outperformed C T. The study has been criticized for lack of integration of a diagnostic contrasted CT into the 
PET/CT acquisition algorithm, although PET/CT results were interpreted with knowledge of a separate contrasted 
diagnostic CT; such integration enhances per -lesion sensitivity and specificity in head and neck cancer staging71 and is 
of theoretical utility in the post -treatment patient. The CT criteria used in the MDACC study to classify nodal disease 
were clinical and related to REC IST. However, long axis nodal measurements were utilized with the following  
categorization:  
• Pathologic (residual disease) nodes: > [ADDRESS_912356] diameter and/or necrotic  appearance.  
• Indeterminate nodes: [ADDRESS_912357]  findings.  
• Non-pathologic nodes: < [ADDRESS_912358] diameter and non -necrotic  (CR).  
 
At the University of Pi[INVESTIGATOR_9109], the standard of care following definitive chemoradiotherapy for PULA HNSCC has 
been integrated PET/CT. Following PET/CT patients are placed into four clinical categories: Negative PET/CT 
(Complete Response); Probably Negative PET/CT (Low clinical concern; follow up indicated); Probably Positive 
PET/CT (Clinical concern; tissue sampling indicated); Positive PET/CT (Definite residual disease). T his 
categorization has been found to correlate with clinical outcomes, specifically PFS.72 
Definition of CR following chemoradiotherapy therefore has two relevant, literature -based definitions which may be of 
clinical utility: 1) Quantitative anatomic criteria (RECIST 1.1); 2) Integrated PET/CT criteria.  
  
 
Complete Response: Modified RECIST 1.1 (see section 6.1)  
 
• Disappearance of primary tumor. Irregular contour of the tumor bed is consistent with -radiation  change.  
• Decrease in measurable pathologic neck lymph nodes to short axis measurement < 10 mm and 
non-necrotic appearance with normalization of nodal configuration. Increased enhancement may 
be attributable to radiation  change.  
• No new pathologic  lesions.  
 
7. DRUG  INFORMATION  
7.1 Pembrolizumab  
7.1.1 Study Drug  Materials  
Pembrolizumab drug substance is produced at two locations to yield: 1) a partially formulated aqueous solution 
stored under refridgerated conditions (2 -8˚C) at a concentration of 40 -50 mg/mL in 10 mM histidine buffer, pH 5.2 -
6.8, and 2) a fully formulated aqueous solution stored frozen ( -40˚C) at a concentration of 22.5 -27.5 mg/mL in 10 
mM histidine buffer, pH 5.2 -5.8 containing 7% sucrose and 0.02% polysorbate 80. The drug products are sterile 
filtered into Type I glass vials intended for single use.  
Two drug product dosage forms are available for pembrolizumab: 1) a white to off -white lyophilized powder, 50 
mg/vial, and 2) a liquid, 100 mg/vial.  
• Pembrolizumab Powder for Solution for Infusion, 50  mg/vial (manufactured using the partially formulated 
drug substance), is reconstituted with sterile water for injection prior to use. It is formuated with L -histidine 
as buffering agent, polysorbate 80 (surfactant), sucrose as stabilizer/tonicity modifier , and hydrochloric acid 
(HCl) and/or sodium hydroxide (NaOH) for pH adjustment (if  necessary).  
• Pembrolizumab Solution for Infusion, 100 mg/vial is a liquid drug product (manufactured using the fully 
formulated drug substance), and has the identical formula tion as that of the reconstituted lyophilized  vial. 
The product after reconstitution with sterile water and the liquid drug product are a clear to opalescent solution which 
may contain proteinaceous and extraneous particulates.  
Both the pembrolizumab recon stituted product and the liquid product are intended for IV administration and both 
can be further diluted with normal saline in IV containers made of polyvinyl chloride (PVC) or non -PVC 
material.  
  
 
7.1.[ADDRESS_912359] dosage forms are to be stored 
under refrigerated conditions (2o C– 8oC) and in a secure location.  
Note:  No other  use of pembrolizumab  study  drug intended  for use in this trial  is authorized  by [CONTACT_456].  The 
investigator  (or designee)  will be responsible for the appropriate handling and disposition of residual study drug in 
partially used  vials.  
Vial Labels: Pembrolizumab vial labels will bear the appropriate label text for investigational agents, as 
required by [CONTACT_675074].  
Complete study drug information (including packaging, labeling, storage and disposition) is provided in the 
Pembroliuzumab Investigator’s Brochure (IB).  
7.2 Cisplatin  
Refer to the package insert for additional information.  
Formulation : Eac h vial contains [ADDRESS_912360] pH.  
Mechanism of Action:  The dominant mode of action of cisplatin appears to be inhibition of the incorporation of DNA 
precursors, although protein and RNA synthesis are also inhibited. Although this drug seems to act as an alkylating agent, 
there are data to indicate that its mode and sites of action are different from those of nitrogen mustard and the standard 
alkylating agents.  
Administration:  Cisplati n will be given as a bolus, infused over 1 -2 hours along with appropriate hydration and anti -
emetics.  
Storage and Stability:  Reconstituted solution of cisplatin is stable for 20 hours when stored at 27°C and should be 
protected from light if not used withi n [ADDRESS_912361] with aluminum needles, producing a black precipi[INVESTIGATOR_160591] 30 minutes.  
Adverse Events:  Human toxicity includes nausea, vomiting, renal toxicity (with an eleva tion of BUN and creatinine 
and impairment of endogenous creatinine clearance, as well as renal tubular damage, which appears to be transient), 
ototoxicity (with hearing loss that initially is in the high -frequency range, as well as tinnitus), and hyperuric emia. 
Much more severe and prolonged toxicity has been observed in patients with  
  
 
abnormal or obstructed urinary excretory tracts. Myelosuppression, often with delayed erythrosuppression, is expected.  
Supply:  Cisplatin is commercially available. The use of drug(s) or combination of drugs in this protocol meets the 
criteria described under Title 21 CFR 312.2(b) for IND exemption.  
8. CLINICAL AND LABORATORY  EVALUATIONS  
Schedule of Assessments. See Appendix C for St udy Calendar.  
8.1 Pre-Registration  Evaluations  
NOTE: This section lists baseline evaluations that are required for registration. Evaluations should be 
performed within 4 weeks of registration unless otherwise indicated.  
8.1.1  Required Pre -Registration  Evaluati ons 
• History and physical examination, including vital signs, weight, height and ECOG performance status  
determination.  
• Complete blood count, including platelets and  differential.  
• Blood chemistry studies (may be obtained from whole blood or serum/plasma samples), including BUN, 
creatinine, electrolytes (K+, Na+, CI-, CO 2), glucose, calcium, Mg++ and liver function tests (total protein, 
albumin, total bilirubin, AST (SGOT), ALT (SGPT), and  alkaline  phosphatase), uric acid, and lactate  
dehydrogenase.  
• Coagulation studies, including prothrombin time (PT), international normalized ratio (INR), and activated 
partial thromboplastin time (aPTT).  
• Thyroid function tests, including thyroid stimulating hormone (TSH), free thyroxine, (FT4), anti -thyroglobulin 
antibody, thyroid peroxidase antibody, thyroid stimulating immunoglobulin, and ANA. Establishing baseline 
thyroid function and pre -existing thyroid auto - immunity is required, as an appropriate clinical standard prior to 
chemoradiotherapy for HNSCC as well as  anti-PD1 therapy for HNSCC. However, normal thyroid function 
and absence of subclinical thyroid auto -immunity (example detectable anti -thyroglobulin antibody or 
detectable thyroid peroxidase antibody) are not eligibility criteria. If subclinical hypothyro idism is detected, 
treatment should be initiated according to standard practice. If subclinical thyroid auto -immunity is detected, 
the patient is still  eligible.  
• For women of child bearing potential: Urine or blood pregnancy test within 2 weeks  of registra tion to 
rule out pregnancy. (Note, pregnancy test will be repeated within 3 days of initiating protocol  
treatment.)  
• Baseline tumor measurements within [ADDRESS_912362] scan (e.g. history of allergic reaction to iodinated contrast despi[INVESTIGATOR_250896]), MRI of the 
neck may be conducted for baseline tumor measurements. Note : when feasible, a baseline integrated 
PET/CT with diagnostic contrasted CT scan is preferred. Any scans or x -rays used to document measurable 
disease should be done as close to study entry as possible and within 4 weeks prior to  registration . 
  
 
• Evaluatio n by [CONTACT_675075], within 8 weeks prior to registration. 
Endoscopy for oropharyngeal carcinoma may be performed as clinically indicated. Endoscopy is 
required for hypopharyngeal and laryngeal  carcinoma.  
• For oropharyngeal or unknown primary cases: HPV status must be known or established and recorded at  
baseline.  
• Tobacco history assessment form (See Appendix  A). 
 
 
8.1.2 Recommended Pre -Treatment  Evaluations  
Note: This section lists baseline evaluations recommended but not required  before the initiation of 
protocol treatment. These evaluations do not affect eligibility.  
• An audiogram within 12 weeks prior to start of protocol treatment and 8 to 12 weeks after IMRT is  complete  
• Dental evaluation and if applicable, prophylaxis, within [ADDRESS_912363] radiotherapy  treatment.  
• Patients  should  be provided  with dental  education  including  the risk for radiation -induced  dental  decay,  
methods  for maintaining  good  oral hygiene, and use of prescription fluoride treatment. Ap propriate oral 
hygiene includes the following: brushing teeth after each meal, flossing daily, the frequent use of oral rinses 
with Salt and/or Baking Soda (every two to four hours), and the daily use of prescription fluoride  therapy.  
• Nutritional Evaluatio n. It is strongly encouraged that all patients undergo an initial dietary assessment by a 
trained dietician, prior to start of protocol treatment. Patients with weight loss and inadequate oral intake 
should be strongly considered for a feeding tube prior t o initiation of therapy. For patients with adequate oral 
intake, the prophylactic placement of a feeding tube is at the discretion of the treating physician. Patients 
should be followed by [CONTACT_675076]. Dietary re commendations 
should include: recommended total caloric intake, recommended intake of protein, daily requirement for free 
water, and the appropriate use  of 
  
 
supplements. Should it become evident at any time during therapy that oral intake is inadequate, a feeding tube 
should be placed. Close monitoring by [CONTACT_675077], particularly 
immediately after tube placement as patients often experience problems with enteral feeding or formulations. 
All patients who have a feeding tube placed should be referred to Speech and Language Pathology (SLP) for 
swallowing exercises to minimize disuse atrophy. In addition, post -treatment, it is critical to work with the 
SLP and dietician to identify when it is s afe and appropriate for patients to return to oral intake. Patients should 
be encouraged to wean themselves off their feeding tubes as soon as possible in order to maximize swallowing 
outcomes.  
• Speech and Language Pathology (SLP). It is strongly encouraged  that all patients undergo swallowing 
assessment and therapy prior to  the start of protocol treatment. Swallowing assessment and therapy should be 
considered a critical component of care for all head and neck cancer patients undergoing concurrent therapy. 
Assessments should be done by a trained Speech -Language Pathologist. SLP should be consulted during 
treatment planning and should provide routine follow -up throughout the trajectory of the patient’s treatment 
and recovery. The treating physician should com municate with SLP in order to coordinate care in those 
patients found to have significant swallowing abnormalities. Critical component of the swallowing evaluation 
should include: 1) identification of any swallowing abnormalities, 2) recommendations for fu rther testing, 3) 
formation of a treatment plan, 4) dietary recommendations and 5) clear identifications of patients at risk for 
aspi[INVESTIGATOR_1516]. Patients should be referred immediately for evaluation if any of the following “trigger symptoms” 
are identified: c oughing or clear the throat before, during or after eating, inability to control food, liquids or 
saliva in the oral cavity,  complaint of  difficulty  swallowing  or food “sticking”  in the throat,  nasal regurgitation  
of food,  or pocketing  of food in the cheek . 
 
8.2 Evaluations during  treatment  
8.2.1 Arm 1 (Cisplatin -IMRT followed by [CONTACT_675056])  
ARM 1, WEEKS 1 -7 (During 
concurrent cisplatin -IMRT) 
Weekly:  
Note: The following assessments will be performed weekly and may be performed on the day of or 
the day prior to cisplatin administration.  
 
• History and physical  examination.  
• Vital signs, including  weight.  
• Toxicity assessment with  attribution.  
• Update of concomitant  medications.  
  
 
• Complete blood count, including platelets and  differential.  
• Blood chemistries (may be obtained from whole blood or serum/plasma sample), including creatinine, 
electrolytes (K+, Na+,  CI-, CO2), calcium, Mg++ and liver function tests [bilirubin, AST (SGOT), 
ALT (SGPT), and alkaline phosphatase, total protein, albumin ]. 
 
Every 3 weeks (Week 3 and Week 6):  
 
Note: The following assessments will be performed every [ADDRESS_912364] of care blood draw, to minimize needle sticks 
to the patient.  
 
• Thyroid function tests (TSH,  FT4).  
 
 
Once (Week 6):  
 
• Anti-thyroglobulin antibody, thyroid peroxidase antibody, thyroid stimulating immunoglobulin, and  
ANA.  
 
ARM 1, WEEKS 8 -31 (During sequential 
pembrolizumab treatment): Every 3 
weeks (Week 9, 12, 15, 18, 21, 24, 25, 
30): 
Note: The following assessments will be performed every 3 weeks, and may be performed on the day of or the 
day prior to pembrolizumab administr ation.  
  
 
• History and physical  examination.  
• Vital signs, including  weight.  
• Toxicity assessment with attribution, including irAE  assessment.  
• Update of concomitant  medications.  
• Complete blood count, including platelets and  differential.  
• Blood chemistries (may be obtained from whole blood or serum/plasma sample), including creatinine, 
electrolytes (K+, Na+,  CI-, CO2), calcium, Mg++ and liver function tests [bilirubin, AST (SGOT), 
ALT (SGPT), and alkaline phosphatase, total protein, albumin ] . 
• Thyroid function tests (TSH,  FT4).  
 
Twice (Week 18, Week 30; these will be performed at the 4th and 8th doses of pembrolizumab, respectively):  
 
• Anti-thyroglobulin antibody, thyroid peroxidase antibody, thyroid stimulating immunoglobulin, and  
ANA.  
 
8.2.2 Arm 2 (Concurrent pembrolizumab, cisplatin and  IMRT)  
ARM 2, WEEKS -1 to +7 (During concurrent 
pembrolizumab, cisplatin -IMRT) Weekly:  
Note: The following assessments will be performed weekly starting Week -1, and may be performed 
on the day of or the day prior to pembrolizumab and/or cisplatin administration.  
 
• History and physical  examination.  
• Vital signs, including  weight.  
• Toxicity assessment with attribution, including irAE  assessment.  
• Update of concomitant  medications.  
• Complete blood count, including platelets and  differential.  
• Blood chemistries (may be obtained from whole blood or serum/plasma sample), including creatinine, 
electrolytes (K+, Na+,  CI-, CO2), calcium, Mg++ and liver function tests [bilirubin, AST (SGOT), 
ALT (SGPT), and alkaline phospha tase, total protein, albumin].  
  
 
Every 3 weeks (Week 3 and Week 6):  
 
Note: The following assessments will be performed every 3 weeks during concurrent pembrolizumab, 
cisplatin -IMRT, and may be performed on the day of or the day prior to cisplatin/pembrolizumab 
administration. It is recommended that research blood should be coupled to the standard of care blood 
draw, to minimize needle sticks to the patient.  
 
• Thyroid function tests (TSH,  FT4).  
 
 
 
Once (Week 6):  
 
• Anti-thyroglobulin antibody , thyroid peroxidase antibody, thyroid stimulating immunoglobulin, and  
ANA.  
 
ARM 2, WEEKS 8 -25 (During sequential 
pembrolizumab treatment): Every 3 
weeks (Week 9, 12, 15, 18, 21):  
Note: The following assessments will be performed every 3 weeks, and may be performed on the day of or the 
day prior to pembrolizumab administration.  
 
• History and physical  examination.  
• Vital signs, including  weight.  
• Toxicity assessment with attribution, including irAE  assessment.  
• Update of concomitant  medications.  
  
 
• Complete blood count, including platelets and  differential.  
• Blood chemistries (may be obtained from whole blood or serum/plasma sample), including creatinine, 
electrolytes (K+, Na+,  CI-, CO2), calcium, Mg++ and liver function tests [bilirubin, AST (SGO T), 
ALT (SGPT), and alkaline phosphatase, total protein, albumin].  
• Thyroid function tests (TSH,  FT4).  
 
Twice (Week 9, Week 21; these will be performed at the 4th and 8th doses of pembrolizumab, respectively):  
 
• Anti-thyroglobulin antibody, thyroid peroxidas e antibody, thyroid stimulating immunoglobulin, and  
ANA.  
 
8.[ADDRESS_912365]-treatment  Evaluations  
8.3.1 Response  Assessment  
[IP_ADDRESS]  RECIST 1.1. Response assessment by [CONTACT_393] 1.1 is required; integrated PET/CT 
interpretation is  strongly recommended where  available.  
Twelve to 14 weeks  following completion of cisplatin -IMRT (week 20 -22 of protocol 
treatment), patients on both treatment arms will undergo diagnostic contrasted CT 
scan of the neck and chest, to assess treatment response according to RECIST 1.1. In 
the case where MRI of the  neck was required for baseline tumor measurements, 
MRI of the neck should be repeated for response assessment, with non -contrasted 
diagnostic CT of the chest. Note: where available, an integrated PET/CT with 
contrasted diagnostic CT scans of the neck and chest is strongly preferred for 
response assessment.  
[IP_ADDRESS]  Evaluation by [CONTACT_675078].  
[IP_ADDRESS]  The patient will be evaluated by [CONTACT_675079] 12 -14 weeks following completion of 
cisplatin -IMRT (during weeks 20 -22). Endoscopy for  oropharyngeal or unknown primary carcinoma 
will be performed for response assessment as clinically indicated, and is at the discretion of the 
surgeon. Endoscopy is required for hypopharyngeal and laryngeal  carcinoma. The surgeon will 
evaluate the need for  primary site biopsy and/or neck  dissection.  
  
 
8.3.2 End of Treatment Visit(s): Week 33 (+/ - 2 weeks) for Arm 1; Week 24 (+/ - 2 weeks) for Arm 
2. Patients will undergo the following procedures at the end of treatment  visit:  
 
• History and physica l examination and performance  status.  
• Assessment for resolution of toxicities, including irAE, with  attribution.  
• Thyroid function testing (TSH, T3,  FT4).  
• Complete blood count, including platelets and  differential.  
• Blood chemistries (may be obtained from whole blood or serum/plasma sample), including BUN, creatinine, 
electrolytes (K+, Na+,  CI-, CO2), calcium, Mg++ and liver function tests (bilirubin, AST (SGOT), ALT 
(SGPT), and alkaline phosphatase, total protein,  albumin).  
• Audiogram assessment as  indicate d. 
 
8.3.3 Surgical  Consolidation  
The necessity for and the timing of surgical consolidation will be determined by [CONTACT_11065]. If patients undergo 
surgical consolidation, tumor tissue should be submitted for correlative study.  
Primary Site  
Surgery will be perfor med in the setting of resectable residual disease if the patient is considered a surgical candidate 
and: 
1) Definitive radiotherapy was not completed, and radiographic or clinical evidence of persistent or progressive disease 
is established.  
2) Biopsy -proven dis ease is demonstrated at the primary site and/or neck at least 8 -12 weeks after completion of 
IMRT. In cases of residual disease at the primary site, the neck will always be dissected at the time of surgical 
salvage (if neck dissection was not previously co nducted at post -protocol biopsy).  
Surgical Management of the Neck  
Neck dissection will be performed, if there is concern for residual disease. The extent of neck dissection will be 
determined by [CONTACT_11065]. The consideration to perform less than radical procedures is strongly encouraged if 
oncologically safe. Note: the presence of residual disease at surgical consolidation, if performed within 24 weeks of 
completion of IMRT, will not constitute a progression event.  
  
 
8.4 Long Term Follow  Up 
After the end of treatment visit, patients will be evaluated every 3 months for 21 months (+/ - 2 weeks), then every 6 
months (+/ - 1 month) for one year, then annually (+/ - 1 month) for two years, which will represent a total of 5 years 
from completion of I MRT. Thus, long -term follow -up evaluations will start approximately 6 months after completion 
of IMRT, and will include the following:  
• History and physical examination and performance  status.  
• Vitals signs, including  weight.  
• Assessment for late toxicity, in cluding dysphagia, xerostomia, gastrostomy tube dependence, pain, fibrosis 
and lymphedema within the head and neck, hypothyroidism, late autoimmune  events.  
• Thyroid function testing (TSH,  FT4).  
• Complete blood count, including platelets and  differential.  
• Blood chemistries (may be obtained from whole blood or serum/plasma sample), including BUN, creatinine, 
electrolytes (K+, Na+,  CI-, CO2), calcium, Mg++ and liver function tests (bilirubin, AST (SGOT), ALT 
(SGPT), and alkaline phosphatase, total protein,  albumin)  
• During the long term follow -up period, tumor assessments will be performed 6, 9, 12, 18, 24, 36, 48, and 60 
months after completion  of radiotherapy (+/ - one month). The minimum protocol imaging requirement is: 
contrasted, diagnostic neck and chest  CT at intervals specified above. More intensive imaging may be 
conducted per local  practice.  
• Swallowing assessments per local practice and as indicated by [CONTACT_447] -radiotherapy evaluation and patient -reported  
symptoms.  
• Note: patients who have documented progr ession may discontinue scheduled study assessments and will be 
followed only for survival. Survival assessments will be performed every 6 months (+/ - 2 months) by 
[CONTACT_675080]/or by [CONTACT_675081].  
 
 
9. STATISTICAL METHODS  
This is a randomized, parallel group, non -comparative phase II trial evaluating the safety and efficacy of two schedules of 
fixed -dose pembrolizumab combined with standard cisplatin -IMRT in intermediate or high risk, PULA HNSCC:  
sequential and concurrent. This study is being performed in order to provide: a) necessary safety experience; b) 
preliminary efficacy estimates; c) characterization of the PD -L1 biomarker in the context of definitive chemoradiation; d) 
the recommended sch edule for definitive testing.  
 Primary Objective  
To evaluate two schedules of fixed -dose pembrolizumab (concurrent vs. sequential) added to standard, concurrent 
cisplatin -IMRT in patients with PULA HNSCC, in order to recommend  the schedule to be tested in  a subsequent 
definitive, randomized study.  
 Sample Size Determination  
The target sample size is 40 evaluable patients per arm. Assuming 10% drop out or ineligibility, 90 patients will be 
randomized (all evaluable patients will be analyzed). The sample siz e is determined based upon the following 
assumptions: 1) the 1 -year PFS in the high risk population treated with conventional cisplatin -radiotherapy is 60%;6 2) As 
defined, DLTs occurring in more than 20% of the study population are unacceptable and would constitute an unsafe 
regimen; 3) The study requires adequate power to detect a signal of antagonism, defined as a 1 -year local failure rate 
 exceeding 60%. To advance to Phase II/III testing, a treatmen t arm must meet all of the following criteria:  
• DLT occurs in ≤ 20%  
• 1-year local failure rate is < 60% 
• 1-year PFS is ≥ 60% 
If both arms meet the above criteria, then the treatment arm demonstrating numerically superior 1 -year PFS will advance 
for definiti ve testing, as in a so -called “pi[INVESTIGATOR_9696] -the-winner” trial model. An early phase trial cannot provide the statistical 
power required for a formal statistical comparison between arms.  
The graphic in Figure 1 below demonstrates the probability of accepting either  treatment (that is, based on n = 40 
evaluable patients  per arm ) by [CONTACT_3553] 90% one -sided exact confidence intervals (CI) for DLT, 1 -year failure rate, and 1 -
year PFS.  If the upper bound of the DLT CI is less than 0.20, the upper bound of the failure CI is less than 0.60, and the 
lower bound of the 1 -year PFS CI is greater than 0. 60, the treatment will be accepted.  
 
Figure 1 : Probability of accepting the treatment according to the three primary metrics  
 
 
 
 Early Stoppi[INVESTIGATOR_675041] (DLT;  see Section 5.8 for DLT definition) will be continuously monitored in both treatment arms, 
and is explicitly intended for the purposes of safety monitoring of the concurrent combination of pembrolizumab and 
cisplatin -IMRT (Arm 2). As defined, excess DLT i s not expected during standard of care cisplatin -IMRT. Excess DLT in 
either arm, however, would trigger the early stoppi[INVESTIGATOR_1877]. A continuous Bayesian stoppi[INVESTIGATOR_675042], once [ADDRESS_912366] accrued to either treatment arm. For either arm, if p (p(DLT)>0.2) ≥ 0.6, then the stoppi[INVESTIGATOR_675043].  Table 11 describes the number of DLTs per number of treated patients required to trigger the early stoppi[INVESTIGATOR_10035], which will require a suspension of accrual to that Arm and evaluation of toxic ity data by [CONTACT_941] H&N Program DSMC to 
determine further action .  
Table 11. Boundaries for the Early Stoppi[INVESTIGATOR_675044]  
0.05 0.10 0.15 [IP_ADDRESS].[IP_ADDRESS]
True P(DL T)P(Accept Treatment)
0.3 0.4 0.5 0.6 [IP_ADDRESS].[IP_ADDRESS]
True P(Local F ailure)P(Accept Treatment)
0.50 0.60 0.70 [IP_ADDRESS].[IP_ADDRESS]
True P(1−Y ear PFS)P(Accept Treatment)
  [ADDRESS_912367] (Klopper -Pearson) 90% confidence intervals.  Adverse events will be tabulated by [CONTACT_416815].  The 
relationship between the three primary metrics and baseline PD -L1 expression will be assessed using logistic regression.    
 
 Secondary Endpoints  
Toxicity  
All patients will be evaluable for toxicity from the time of their first treatment with pembrolizumab. The proportion of 
DLTs in each dosing arm (concurrent vs. sequential)  will be reported, as will the proportion of AEs in accordance with 
NCI CTCAE v.[ADDRESS_912368] -limit (Kaplan -Meier) survival function 
estimat es with appropriate confidence intervals.  The study is not adequately powered for a formal test comparing PFS 
between arms.  
 
 
  
 
10. LABELING, PACKAGING, STORAGE AND RETURN OF 
CLINICAL  SUPPLIES [ADDRESS_912369] Name & Potency  Dosage Form  
Pembrolizumab 50 mg  Lyophilized Powder for Injection  
Pembrolizumab 100 mg/ 4mL  Solution for In jection  
 
10.2 Packaging and Labeling  Information  
Clinical supplies will be affixed with a clinical label in accordance with regulatory requirements.  
Clinical Supplies Disclosure  
This trial is open -label; therefore, the subject, the trial site personnel, the Sponsor and/or designee are not blinded 
to treatment. Drug identity (name, strength) is included in the label text; random code/disclosure envelopes or 
lists are not provided.  
10.3Storage and Handling  Requirements  
Clinical supplies must be stored in a secure, limited -access location under the storage 
conditions specified on the label. Receipt and dispensing of trial medication must be 
recorded by [CONTACT_131895].  
Clinical supplies may not be used for any purpose other than that stated in the protocol.  
10.4 Returns and  Reconciliation  
The investigator is responsible for keepi[INVESTIGATOR_628449], the 
amount dispensed to and  
  
 
returned by [CONTACT_110535].  
Upon completion or termination of the study, all unused and/or partially used investigational product will be destroyed 
at the site per institutional policy. It is the Investigator’s responsibility to arrange for d isposal of all empty containers, 
provided that procedures for proper disposal have been established according to applicable federal, state, local and 
institutional guidelines and procedures, and provided that appropriate records of disposal are kept.  
[ADDRESS_912370] medical occurrence associated with the use of the drug in humans, whether or not 
considered drug related.  
Suspected adverse reaction. Any adverse event for which there is a reasonable possibility that the drug caused the adverse 
event (considered “possibly related”). For the purposes of safety reporting, "reasonable possibility" means there is 
evidence to suggest a causal relationship between the drug and the  adverse event. Suspected adverse reaction implies a 
lesser degree of certainty about causality than adverse reaction, which means any adverse event caused by a drug.  
Adverse reaction means any adverse event caused by a drug. Adverse reactions are a subset  of suspected adverse 
reactions where there is reason to conclude that the drug caused the event.  
 
 
Serious Adverse Event: Any untoward medical occurrence associated with the use of a drug in humans, whether or not 
considered drug related. Specifically, re sults in death, is life -threatening, requires inpatient hospi[INVESTIGATOR_675045], results in persistent or significant disability/incapacity, is a congenital 
anomaly/birth defect, or is an important medical event ( defined as a medical event(s) that may not be immediately life -
threatening or result in death or hospi[INVESTIGATOR_313], based upon appropriate medical and scientific judgment, may 
jeopardize the subject or may require intervention [e.g., medical, surgical] t o prevent one of the other serious outcomes 
listed in the definition above.) Any subject death within [ADDRESS_912371] dose of study drug, regardless of the causality  
or a secondary malignancy should also be recorded as a serious adverse event.  
Life-threatening, suspected adverse reaction. A suspected adverse reaction is considered “life -threatening” if, in the view 
of either the Investigator (i.e., the study site principal investigator), its occurrence places the patient or research subje ct at 
immediate  risk of death. It does not include a suspected adverse reaction that had it occurred in a more severe form, 
might have caused death.  
  
 
Unexpected, suspected adverse reaction. A suspected adverse reaction is considered “unexpected” if it is not listed in 
the general investigational plan or clinical protocol; or is not listed at the specificity or severity that has been previous ly 
observed and/or specified. If an investigator brochure is not required or available, suspected adverse reaction  is not 
consistent with the risk information described in the general investigational plan or elsewhere in the current application, 
as amended. "Unexpected," as used in this definition, also refers to adverse events or suspected adverse reactions that 
are mentioned in the investigator brochure as occurring with a class of drugs or as anticipated from the pharmacological 
properties of the drug, but are not specifically mentioned as occurring with the particular drug under investigation. Any 
clinically import ant increase in the rate of a serious suspected adverse reaction over that listed in the protocol or 
investigator brochure can also be considered unexpected. An aggregate analysis of specific events observed in a clinical 
trial (such as known consequences of the underlying disease or condition under investigation or other events that 
commonly occur in the study population independent of drug therapy) that indicates those events occur more frequently 
in the drug treatment group than in a concurrent or histor ical control  group.  
All observed or volunteered adverse events (serious or non -serious) and abnormal test findings, regardless of study 
group or suspected causal relationship to the study drug(s) will be recorded in the subjects’ case histories. For all 
adverse events, sufficient information will be pursued and/or obtained so as to permit 1) an adequate determination of 
the outcome of the event (i.e., whether the event should be classified as a serious adverse event) and; 2) an assessment 
of the casual re lationship between the adverse event and the study drug(s). All toxicities encountered during the study 
will be evaluated on an ongoing basis according to the NCI Common Toxicity Criteria version 4.0.  
Adverse events or abnormal test findings felt to be ass ociated with the study drug(s) will be followed until the 
event (or its sequelae) or the abnormal test finding resolves or stabilizes at a level acceptable to the Principal 
Investigator.  
 
 
In the event of an adverse event the first concern will be for the safety of the subject.  
 
 
11.2 Review of safety information. The principal investigator / sponsor must promptly review all 
information relevant to  the safety of the drug obtained or otherwise received from foreign or 
domestic sources, including information deriv ed from any clinical or epi[INVESTIGATOR_675046], animal or in vitro studies, reports in the scientific literature, and unpublished 
scientific papers, as well as reports from foreign regulatory authorities and reports of foreign 
commercial marketing experience for drugs that are not marketed in the [LOCATION_002]. The 
study sponsor must notify  all 
  
 
participating investigators of potential serious risks, from clinical trials or any other source, as 
soon as possible. Definition of an O verdose for This Protocol and Reporting of Overdose to the 
Sponsor and to [COMPANY_006].  
 
For purposes of this trial, an overdose of pembrolizumab will be defined as any dose of 1,000 mg or greater (≥5 times 
the indicated dose). No specific information is available on the treatment of overdose of pembrolizumab. Appropriate 
supportive treatment should be provided if clinically indicated. In the event of overdose, the subject should be observed 
closely for signs of toxicity. Appropriate supportive treatment s hould be provided if clinically indicated.  
If an adverse event(s) is associated with (“results from”) the overdose of pembrolizumab, the adverse event(s) is 
reported as a serious adverse event, even if no other seriousness criteria are met.  
If a dose of pembrolizumab meeting the protocol definition of overdose is taken without any associated clinical 
symptoms or abnormal laboratory results, the overdose is reported as a non -serious Event of Clinical Interest (ECI), 
using the terminology “accidental or int entional overdose without adverse effect.”  
All reports of overdose with and without an adverse event must be reported within 24 hours to the Sponsor and within 2 
working days to [COMPANY_006] Global Safety (Attn: Worldwide Product Safety; FAX 215 993 -1220) using the departmental 
SAE form or on a Form FDA [ADDRESS_912372] (spontaneously reported to them), including the pregnancy of 
a male subject's female partner that occurs during the trial or within [ADDRESS_912373] be followed to the completion/termination of 
the pregnancy. Pregnancy outcomes of spontan eous abortion, missed abortion, benign hydatidiform mole, blighted 
ovum, fetal death, intrauterine death, miscarriage and stillbirth must be reported as serious events (Important Medical 
Events). If the pregnancy continues to term, the outcome (health of i nfant) must also be reported.  
Such events must be reported within 24 hours to the Sponsor and within 2 working days to [COMPANY_006] Global Safety (Attn: 
Worldwide Product Safety; FAX 215 993 -1220) using the departmental SAE form or on a Form FDA 3500 
MedWatch . 
  
 
11.4 Immediate Reporting of Adverse Events to the Sponsor, Institutional IRB, and to  [COMPANY_006]  
12.4.1  Serious Adverse  Events  
A serious adverse event is any adverse event occurring at any time during protocol treatment with 
pembrolizumab, cisplatin and IMRT that:  
 
• Results in  death.  
• Is life  threatening.  
• Results in persistent or significant disability/incapacity.  
• Results in or prolongs an existing inpatient hospi[INVESTIGATOR_059] (NOTE: Elective outpatient procedures for 
feeding tube placement do not constitute S AEs in this  protocol.)  
• Is a congenital anomaly/birth  defect.  
• Is a new cancer (that is not a condition of the  study).  
• Is associated with an  overdose.  
• Is another important medical  event.  
 
Refer to Table 13 below for additional details regarding each of the above criteria.  
 
For the time period beginning when the consent form is signed until treatment allocation/randomization, any 
serious adverse event, or follow  up to a serious  adverse  event,  including  death  due to any cause  that occurs  to 
any subject  must  be reported  within  [ADDRESS_912374]  to be excluded  
from  the trial, or is the result  of a protocol -specified  intervention,  including  but not limited  to washout or 
discontinuation of usual therapy, diet, placebo treatment or a  procedure.  
 
For the time period beginning at treatment allocation/randomization through [ADDRESS_912375] be followed up for outcome.  
 
SAE reports an d any other relevant safety information are to be forwarded to the [COMPANY_006] Global Safety 
facsimile number:  [PHONE_13997]- 993-[ADDRESS_912376] (ECI) and must 
be reported within 24 hours to the Sponsor and within 2 working days to [COMPANY_006] Global Safety (Attn: Worldwide 
Product Safety; FAX 215 993 -1220) using the departmental SAE form or on a Form FDA 3500 MedWatch.  
 
For the time period beginning when the cons ent form is signed until treatment allocation/randomization, any 
ECI, or follow up to an ECI, that occurs to any subject must be reported within [ADDRESS_912377] to be exclude d from the trial, or is the 
result of a protocol -specified intervention, including but not limited to washout or discontinuation of usual 
therapy, diet, or placebo treatment.  
For the time period beginning at treatment allocation/randomization through [ADDRESS_912378] for this trial include:  
 
1. An overdose  of pembrolizumab,  as defined  in Section  12.[ADDRESS_912379] of 
protocol -specified laboratory testing or unscheduled laboratory  testing.*  
  
 
*Note:  These criteria are based upon available regulatory guidance documents. The purpose of the criteria 
is to specify a threshold of abnormal hepatic tests that may require an additional evaluation for an 
underlying etiology.  
 
12.4.3  Evaluating Adverse  Events  
Table 1 3. Evaluating Adverse Events  
 
An investigator who is a qualified physician, will evaluate all adverse events as to:  
 
V4.0  CTCAE  
Grading  Grade 1  Mild; asymptomatic or mid symptoms; clinical or diagnostic observations only; intervention not indicated.  
 Grade  2 Moderate; minimal, local or noninvasive intervention indicated; limiting age -appropriate instrumental ADL.  
 Grade 3  Severe or medically significant but not immediately life -threatening; hospi[INVESTIGATOR_130978]; disabling; limiting self -care ADL.  
 Grade 4  Life threatening consequences; urgent intervention indicated.  
 Grade 5  Death related to AE  
Seriousness  A serious adverse event is any adverse event occurring at any dose or during any use of pembrolizumab that: 
†Results in death ; or 
†Is life threatening; or places the subject, in the view of the investigator, at immediate risk of death from the event as it occurred 
(Note: This does not include an adverse event that, had it occurred in a more severe form, might have caused death.); or  
†Results in a persistent or significant disability/incapacity (substantial disruption of one’s ability to conduct normal life functions); 
or 
†Results in or prolongs an existing inpatient hospi[INVESTIGATOR_059] (hospi[INVESTIGATOR_19357], regardless of length 
of stay, even if the hospi[INVESTIGATOR_2138] a precautionary measure for continued observation. (Note: Hospi[INVESTIGATOR_059] [including 
hospi[INVESTIGATOR_34096]] for a preexi sting  
condition which has not worsened does not constitute a serious adverse event.. Moreover, Elective hospi[INVESTIGATOR_675047] a serious adverse event); or  
†Is a congenital anomaly/birth defect (in offspring of subject taking the product regardless of time to diagnosis);or  
Is a new cancer; (that is not a condition of the study) or 
Is an overdose (whether accidental or intentional). Any adverse event associated with an overdose is considered a serious adverse 
event. An overdose that is not associated with an adverse event is considered a non -serious event of clinical interest and must be 
reported within [ADDRESS_912380] and may require medical or surgical interventio n to 
prevent one of the outcomes listed previously (designa ted above by a †).  
Duration  Record the start and stop dates of the adverse event. If less than [ADDRESS_912381] to be discontinued?  
Relationship to 
pembrolizumab, 
cisplatin, and/or 
IMRT  Did the pembrolizumab cause the adverse event? The determination of the likelihood that pembrolizumab caused the adverse even t 
will be provided by [CONTACT_19427] a qualified physician. The investigator’s signed /dated initials on the source document or 
worksheet that supports the causality noted on the AE form, ensures that a medically qualified assessment of causality was do ne. 
This initialed document must be retained for the required regulatory time frame. The criteria below are intended as reference 
guidelines to assist the investigator in assessing the likelihood of a relationship between the pembrolizumab and the adverse  event 
based upon the available information. The physician will also take into considerati on the relationship of the adverse event to the 
standard study treatments, cisplatin and IMRT.  
The following components are to be used to assess the relationship between pembrolizumab and the AE ; the greater the 
correlation with the components and their re spective elements (in number and/or intensity), the more likely the pembrolizumab 
caused the adverse event (AE):  
  
 
 
 Exposure  Is there evidence that the subject was actually exposed to the [COMPANY_006] product such as: reliable history, acceptable 
compliance assessment (pi[INVESTIGATOR_692], diary, etc.), expected pharmacologic effect, or measurement of drug/metabolite in 
bodily specimen?  
Time Course  Did the AE follow in a reasonable temporal sequence from administration of the pembrolizumab?  
Is the time of onset of the AE compatible with a drug -induced effect (applies to trials with investigational medicinal 
product)?  
Likely Cause  Is the AE not reasonably explained by [CONTACT_26369], other 
drug(s)//cisplatin/IMRT, or other host or environmental factors  
 
 
Relationship  The following components are to be used to assess the relationship between the test drug and the AE: (continued)  
to 
pembrolizumabm 
cisplatin, and/or 
IMRT  
(continued)  Dechallenge  Was the [COMPANY_006] product discontinued or dose/exposure/frequency reduced?  
If yes, did the AE resolve or improve?  
If yes, this is a positive dechallenge. If no, this is a negative dechallenge.  
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent dis ability; (2) the 
AE resolved/improved despi[INVESTIGATOR_130980]; or (3) the trial is a single -dose drug 
trial); or (4) [COMPANY_006] product(s) is/are only used one time.)  
 Rechallenge  Was the subject re -exposed to pembrolizumab in this study?  
If yes, did the AE recur or worsen?  
If yes, this is a positive rechallenge. If no, this is a negative rechallenge.  
(Note: This criterion is not applicable if the initial AE resulted in death or permanent disability.  
NOTE: IF A RECHALLENGE IS PLANNED FOR AN ADVERSE EVENT WHICH WAS SERIOUS AND 
WHICH MAY HAVE BEEN CAUSED BY [CONTACT_675082], OR IF REEXPOSURE TO 
PEMBROLIZUMAB POSES ADDITIONAL POTENTIAL SIGNIFICANT  
RISK TO THE SUBJECT, THEN THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY [CONTACT_675083] [INVESTIGATOR_675048].  
 Consistency 
with Trial 
Treatment  
Profile  Is the clinical/pathological presentation of the AE consistent with previous knowledge regarding pembrolizumab 
or drug class pharmacology or toxicology?  
The assessment of relationship will be reported on the case report forms /worksheets by [CONTACT_19427] a qualified physic ian according to his/her best 
clinical judgment, including consideration of the above elements.  
Record one of the following  Use the following scale of criteria as guidance (not all criteria must be present to be indicative of 
pembrolizumab relationship).  
Yes, there is a reasonable 
possibility of pembrolizumab 
relationship.  There is evidence of exposure to pembrolizumab. The tempor al sequence of the AE onset relative to the 
administration of pembrolizumab is reasonable. The AE is more likely explained by [CONTACT_675084].  
No, there is not a reasonable 
possibility of 
pembrolizumab relationship  Subject did not receive pembrolizumab OR temporal sequence of the AE onset relative to administration of 
pembrolizumab is not reasonable OR there is another obvious cause of the AE. (Also entered for a subject with 
overdose without an associated AE.)  
[ADDRESS_912382] (per institutional repo rting 
requirements), and [COMPANY_006] will be notified using the the departmental SAE form or FDA Form 3500 
MedWatch.  
All events meeting the definition of a serious adverse event should be recorded on the departmental SAE 
form or on a Form FDA 3500 MedWatch 
(http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM163919.pdf ) and 
submitted to:  
Sponsor -Investigator (Principal Investigator) – within 24 hours of  the Investigator learning of th event  
 
 
David Clump MD  
c/o UPCI Clinical Research Services 
UPMC Cancer Pavilion  
[ADDRESS_912383]., Suite  301 
Pi[INVESTIGATOR_9109], PA  [ZIP_CODE] -1305  
Phone 412 -623-6096  
Fax 412 -623-0004  
[EMAIL_4124]  
 
 
Local Institutional Review Board – timeline per institutional reporting requirements  
[COMPANY_006] Global Safety (Attn: Worldwide Product Safety; FAX 215 993 -1220) – within [ADDRESS_912384] medication information, the report 
should include as applicable the following information that is available at the time of report wi thin the 
Narrative (Section C) on the departmental SAE form or the Event Description (section 5) of the 
Form FDA 3500 MedWatch : 
• CTCAE term(s) and grade(s).  
• current status of study  drug.  
• all interventions to address the AE (testing and result, treatment and  response).  
• hospi[INVESTIGATOR_5478]/or discharge  dates.  
• event relationship to study  drug.  
78 
 Follow -up reports:  
Additional information may be added to a previously submitted report by [CONTACT_675085] 3500 MedWatch and submitting it as follow -up or 
creating supplemental summary information and submitting it as follow -up with the original MedWatch 
3500 form. Data Safety and Monitoring Plan  
The study will be monitored  by [CONTACT_675086]/UPMC Data Safety and Monitoring Committee (DSMC). In 
addition, Investigator/Sub -investigators, regulatory, CRS management, clinical research coordinators, 
clinical research associates, data managers, and clinic staff meet monthly in the head a nd neck cancer 
disease center Data Safety Monitoring Boards (DSMB) to review and discuss study data to include, but 
not limited to, the following:  
• serious adverse  events  
• subject safety  issues  
• recruitment issues  
• accrual  
• protocol  deviations  
• unanticipated  problems  
• breaches of  confidentiality  
 
 
All toxicities encountered during the study will be evaluated on an ongoing basis according to the NCI 
Common Toxicity Criteria version 4.0. All study treatment associated adverse events that are serious, at 
least pos sibly related and unexpected will be reported to the IRB. Any modifications necessary to ensure 
subject safety and decisions to continue, or close the trial to accrual are also discussed during these 
meetings. If any literature becomes available which chan ges the risk/benefit ratio or suggests that 
conducting the trial is no longer ethical, the IRB will be notified in the form of an Unanticipated Problem 
submission and the study may be terminated.  
All study data reviewed and discussed during these meetings will be kept confidential. Any breach in 
subject confidentiality will be reported to the IRB in the form of an Unanticipated Problem submission. 
The summaries of these meetings are forwarded to the UPCI DSMC which also meets monthly following 
a designated format.  
For all research protocols, there will be a commitment to comply with the IRB’s policies for reporting 
unanticipated problems involving risk to subjects or others (including adverse events). DSMC progress 
reports, to include a summary of all seriou s adverse events and modifications, and approval will be 
submitted to the IRB at the time of renewal.  
Protocols with subjects in long -term (survival) follow -up or protocols in data analysis only, will be 
reviewed semi -annually.  
[ADDRESS_912385] access to the research records.  
13. ADMINISTRATIVE AND REGULATORY  DETAILS  
13.1 Quality Control and Quality  Assurance  
Independent monitoring of the clinical study for protocol and GCP compliance will be conducted 
periodically (i.e., at a minimum of annually) by [CONTACT_675087] – 
Human Subject Research, Research Conduct and Compliance Office, University of Pi[INVESTIGATOR_9109].  
The Sponsor -Investigator and the University of Pi[INVESTIGATOR_675049].  
13.[ADDRESS_912386]  Keepi[INVESTIGATOR_675050] -Investigator will maintain records in accordance with Good Clinical Practice guidelines.  
The Sponsor -Investigator will retain the specified records and reports for up to 2 years after the marketing 
application is approved  for the investigational drug; or, if a marketing application is not submitted or 
approved for the investigational drug, until [ADDRESS_912387] (IRB ) approval  
The Sponsor -Investigator will obtain, from the University of Pi[INVESTIGATOR_159499] (IRB), 
prospective approval of the clinical protocol and corresponding informed consent form(s); modifications 
to the clinical protocol and corres ponding informed consent forms, and advertisements (i.e., directed at 
potential research subjects) for study recruitment.  
The only circumstance in which a deviation from the current IRB -approved clinical protocol/consent 
form(s) may be initiated in the abs ence of prospective IRB approval is to eliminate an apparent immediate 
hazard to the research subject(s). In such circumstances, the Sponsor -Investigator will promptly notify the 
University of Pi[INVESTIGATOR_187588].  
The University of Pi[INVESTIGATOR_213163] 21 CFR Parts 50  and 
21 CFR 56 , and in conformance with applicable International Conference on Harmonization (ICH) 
Guidelines on Good Clinical Practice (CGP).  
In the event of the Sponsor -Investigator’s decis ion to modify the previously accepted clinical protocol:  
• For Phase 2 and 3 clinical studies : The Sponsor -Investigator will submit (i.e., in advance of 
implementing the change) a Protocol Amendment to the IRB describing any change to a Phase 2 
or Phase 3 pr otocol that significantly affects the safety of subjects, the scope of the  investigation,  
80 
 or the scientific quality of the study. Examples of Phase 2 and 3 clinical protocol changes 
requiring the submission of a Protocol Amendment include:  
o Any increase in drug dosage or duration of exposure of individual subjects to the 
investigational drug beyond that described in the current protocol, or any  significant 
increase in the number of subjects under  study.  
o Any significant change in the design of t he protocol (such as the addition or deletion of a 
control group).  
o The addition of a new test or procedure that is intended to improve monitoring for,  or 
reduce the risk of, a side effect or adverse event; or the droppi[INVESTIGATOR_31081] a test intended to 
monitor the safety of the investigational  drug.  
13.3.[ADDRESS_912388] of the clinical research  study  
The clinical research study will be conducted in accordance with the current IRB -approved clinical 
protocol; ICH GCP Guidelines adopted by [CONTACT_1622]; and releva nt policies, requirements, and regulations 
of the University of Pi[INVESTIGATOR_68348], University of Pi[INVESTIGATOR_380964], Commonwealth of 
Pennsylvania, and applicable federal agencies.  
13.3.[ADDRESS_912389] to 
ensure that potential research subjects, or their authorized representatives, are fully informed about the 
nature and objectives of the clinical study, the potential risks and benefits of study participat ion, and their 
rights as research subjects. The Sponsor -Investigator, or a sub -investigator(s) designated by [CONTACT_1034] - 
Investigator, will obtain the written, signed informed consent of each subject, or the subject’s authorized 
representative, prior to p erforming any study -specific procedures on the subject. The date and time that 
the subject, or the subject’s authorized representative, signs the informed consent form and a narrative of 
the issues discussed during the informed consent process will be docu mented in the subject’s case history. 
The Sponsor -Investigator will retain the original copy of the signed informed consent form, and a copy 
will be provided to the subject, or to the subject’s authorized representative.  
The Sponsor -Investigator will make certain that appropriate processes and procedures are in place to 
ensure that ongoing questions and concerns of enrolled subjects are adequately addressed and that the 
subjects are informed of any new information that may affect their decision to continue participation in 
the clinical study. In the event of substantial changes to the clinical study or the risk -to-benefit ratio of 
study participation, the Sponsor -Investigator will obtain the informed consent of enrolled subjects for 
continued participation i n the clinical study.  
13.[ADDRESS_912390] (FDAMA) and the Food and 
Drug Administration Amendments Act (FDAAA), the Sponsor of the trial is  solely responsible for 
determining whether the trial and its results are subject to the requirements for submission to the Clinical 
Trials Data Bank, http://www.clinicaltrials.gov.  Information posted will allow subjects to identify 
potentially appropriate trials for their disease conditions and pursue participation by [CONTACT_3379] a central 
contact [CONTACT_57426].  
[ADDRESS_912391], 
pembrolizumab, in accordance with the protocol and any applicable laws and regulations.  
Clinical Supplies will be provided by [CONTACT_80097] 12.  
14.2 Packaging and Labeling  Information  
Clinical supplies will be affixed with a clinical label in accordance with regulatory requirements.  
14.3 Clinical Supplies  Disclosure  
This trial is open -label; therefore, the subject, the trial site personnel, the Sponsor and/or designee are not 
blinded to treatment. Drug identity (name, strength) is included in the label text; random code/disclosure 
envelopes or lists are not provided.  
14.[ADDRESS_912392] be recorded by [CONTACT_131895]. 
Clinical supplies may not be used for any purpose other than that stated in the protocol.  
14.5 Returns and  Reconciliation  
The investigator is respons ible for keepi[INVESTIGATOR_131875], the amount dispensed to and returned by [CONTACT_133624].  
Upon completion or termination of the study, all unuse d and/or partially used investigational product will 
be destroyed at the site per institutional policy. It is the Investigator’s responsibility to arrange for 
disposal of all empty containers, provided that procedures for proper disposal have been establis hed 
according to applicable federal, state, local and institutional guidelines and procedures, and provided that 
appropriate records of disposal are kept.  
82 
 15. APPENDICES  
APPENDIX A: TOBACCO USE ASSESSMENT FORM  
 
1. Have you ever smoked a total of 100  cigarettes (approximately 5 packs) or more  over 
your life-time?  
 
 Yes   No 
 
2. Have you ever smoked cigarettes regularly, that is, at least one cigarette per day for six 
months or  longer?  
 
 Yes   No 
 
3. How old were you when you first started smoking at least one cigarette per  day?  
 
  years  old 
 
4. Do you currently smoke  cigarettes?  
 
 Yes   No 
 
If no, how old were you when you last smoked a cigarette?  
 
  years  old 
 
 
5. Thinking about all the years that you have smoked, how many cigarettes do you (or  did 
you) usually smoke in a  day?  
 1-[ADDRESS_912393] one cigar per day for six  months 
or longer?  
 
 Yes   No 

[ADDRESS_912394] one cigar per  day?  
 
  years  old 
 
8. Do you currently smoke  cigars?  
 
 Yes   No 
 
If no, how old were you when you last smoked a cigar?  
 
  years  old 
 
 
9. How many  cigars did you usually smoke in a  day?  
 
  cigars per day  
 
10. Have you ever smoked a pi[INVESTIGATOR_675051], that is, at least one pi[INVESTIGATOR_675052]?  
 
 Yes   No 
 
11. How old were you when you first started smoking at least one pi[INVESTIGATOR_675053]?  
 
  years  old 
 
12. Do you currently smoke a  pi[INVESTIGATOR_5836]?  
 
 Yes   No 
 
If no, how old were you when you last smoked a pi[INVESTIGATOR_5836]?  
 
  years  old 
 
 
13. Thinking about all the years that you have smoked, how many pi[INVESTIGATOR_675054] (or did  you) 
usually smoke in a  day?  
  pi[INVESTIGATOR_127159]  

84 
 APPENDIX B: PERFORMANCE STATUS CRITERIA  
 
ECOG Performance Status Scale  Karnofsky Performance Scale  
Grade  Descriptions  Percent  Description  
 
 
0  
Normal activity. Fully active, able 
to carry on all pre -disease 
performance without restriction.  100 Normal, no complaints, no 
evidence of disease.  
 
90 Able to carry on normal activity; 
minor signs or symptoms of  
disease.  
 
 
1 Symptoms, but ambulatory. 
Restricted in physically strenuous 
activity, but ambulatory and able 
to carry out work of a light or 
sedentary nature ( e.g., light 
housework, office work).   
80 Normal activity with effort; 
some signs or symptoms of  
disease.  
 
70 Cares for self, unable to carry on 
normal activity or to do active 
work.  
 
 
2 In bed <50% of the time. 
Ambulatory and  capable of all 
self-care, but unable to carry out 
any work activities. Up and about 
more than 50% of waking hours.   
[ADDRESS_912395] of 
his/her needs.  
50 Requires considerable assistance  
and frequent medical care.  
 
 
3 In bed >50% of the time. Capable 
of only limited self -care, confined 
to bed or chair more than 50% of 
waking hours.  40 Disabled, requires special care 
and assistance.  
 
30 Severely disabled, 
hospi[INVESTIGATOR_374]. Death  
not imminent.  
 
4 100% bedridden. Completely 
disabled. Cannot carry on any self - 
care. Totally confined to bed or 
chair.  20 Very sick, hospi[INVESTIGATOR_373]. Death not imminent.  
10 Moribund, fatal processes 
progressing rapi[INVESTIGATOR_375].  
5 Dead.  0 Dead.  
85 
 APPENDIX C: Study Calendars 
Arm 1:  
   
Study Treatment (weeks)  Post  
-tx Long 
Term 
Follow 
Upm 
 Pre 
- 
stu 
dya  
 
1  
 
2  
 
3  
 
4  
 
5  
 
6  
 
7  
 
9  
 
12  
 
15  
 
18  
 
21  
 
24  
 
27  
 
30  
33 +/ - 
2 (at 6,  9, 
12, 18, 
24, 36, 
48, 60 
months)  
Medical 
History, 
PE, Vital 
Signs   
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x 
Height  x                  
Weight  x x x x x x x x x x x x x x x x x x 
ECOG 
PS  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x 
CBC  
with 
Different 
ial b  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x 
Blood 
chemistr 
yc  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x 
Liver 
functiond  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x 
Concomi 
tant meds   
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x 
Pregnanc 
y testn  
x                  
Orophary 
ngeal 
cases, 
p16 
status0  
 
 
 
x                  
Thyroid 
functione  
x    
x    
x   
x  
x  
x  
x  
x  
x  
x  
x  
x  
x 
ANA,  
anti-Tg 
Ab, TPO, 
TSIr  
 
 
x       
 
 
x      
 
 
x     
 
 
x   
86 
 ENT/end 
o-scopy 
evaluatio 
np  
x             
x      
Tobacco 
history   
x                  
Tumor 
measure 
ments, 
RECISTf  
 
 
x             
 
 
x     
 
 
x  
 
 
x 
PET/CTg x            x    x x 
CT neckh x            x    x x 
CT chesti x            x    x x 
Dental 
evaluatio 
nj  
 
x                  
Nutrition 
consultj  
x                  
SLP 
consultj  
x                 
x  
x 
Audiogra 
mj  
x                 
x  
x 
Cisplatin  
q   
x  
x  
x  
x  
x  
x  
x           
Pembroli 
zumab           
x  
x  
x  
x  
x  
x  
x  
x   
IMRT   x x x x x x x           
Adverse 
event 
evaluatio 
n    
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x 
87 
 Arm 2:  
 
   
Study Treatment (weeks)   
Post -tx Long Term 
Follow Upm 
 Pre 
- 
stu 
dy  
-1  
1  
2  
3  
4  
5  
6  
7  
9  
12  
15  
18  
21  
24 +/ - 2 (at 6, 9, 12, 18,  
24, 36, 48, 60  
months)  
Medical 
History, 
PE, Vital 
Signs   
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x 
Height  x                
Weight  x x x x x x x x x x x x x x x x 
ECOG PS  x x x x x x x x x x x x x x x x 
CBC with 
Differenti 
al b  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x 
Blood 
chemistry  
c  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x  
 
x 
Liver 
functiond  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x 
Concomit 
ant meds   
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x  
x 
Pregnanc 
y testn  
x                
Orophary 
ngeal 
cases, 
p16 
status0  
 
 
 
x                
Thyroid 
functione  
x     
x    
x   
x  
x  
x  
x  
x  
x  
x 
ANA,  
anti-Tg 
Ab, TPO, 
TSIr  
 
 
x        
 
 
x   
 
 
x     
 
 
x   
ENT/end 
o-scopy 
evaluatio 
np  
 
 
x                
Tobacco  x                
88 
 history                  
Tumor 
measure 
ments, 
RECISTf  
x                
x 
PET/CTg x               x 
CT neckh x               x 
CT chesti x               x 
Dental 
evaluatio 
nj  
x                
Nutrition 
consultj  
x                
SLP 
consultj  
x                
x 
Audiogra 
mj  
x                
x 
Cisplatinq   x x x x x x x        
Pembroli 
zumab    
x    
x    
x   
x  
x  
x  
x  
x   
IMRT    x x x x x x x        
Adverse 
event 
evaluatio 
n    
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x  
 
 
x 
a. Pre-treatment evaluations will be performed within 4 weeks prior to  registration, unless  otherwise 
specified.  
b. Complete blood count with differential (CBCDs) should include WBC, ANC, PLT, Hb, Hct. 
CBCDs required for protocol therapy may be performed on the day of or the day prior to 
cisplatin/pembrolizumab  administration.  
89 
 c. Blood chemistry should include Na, K, Cl, CO 2, BUN, Cr, Glucose, Ca and Magnesium and be  
either Serum or Whole blood based on institutional  practices/policies.  
d. Liver function tests should include SGOT (AST), SGPT (ALT), total bilirubin, total  protein, 
albumin, alkaline  phosphatase.  
e. Thyroid function studies (TSH, FT4) are required at baseline, and at weeks 3, 6, 9, 12, 15, 18, 21, 
24, 27, 30, and recommended at week 33 f/u (Arm 1); TSH, FT4 is required at baseline, and at weeks 3, 6, 
9, 12, 15, 18, and 21 and recommended at week 24 f/u (Arm 2). TSH and FT4 are required at 6, 9, 12, 18, 
24, 36, 48, and [ADDRESS_912396] will be conducted for staging and tumor 
measurements at baseline, a nd 12 -14 weeks after completing IMRT. If feasible at participating sites, an 
integrated PET/CT with diagnostic contrasted CT is recommended at both time points. Tumor 
measurements will be conducted in accordance with RECIST 1.1. Rare patients may require a n MRI for 
tumor measurements, due to allergy to iodinated contrast despi[INVESTIGATOR_250896]. In these patients, MRI of 
the neck should be performed at baseline and at first response assessment. During long term f/u, neck 
MRI should continue to be performed in  the place of neck  CT. 
g. Integrated PET/CT with diagnostic contrasted neck CT is strongly recommended at pre -study 
baseline and 12 -14 weeks after completing IMRT. However, PET/CT is not required for study 
participation.  
h. CT of the neck (or MRI in those with i odinated contrast allergy) will be conducted at the 
following intervals post IMRT: [ADDRESS_912397] (without contrast in those with iodinated contrast allergy) will b e conducted at  the 
following intervals post IMRT: 6 mos, 9 mos, 12 mos, 18 mos, 24  mos.  
j. These evaluations are strongly encouraged, but not mandatory. See section 5.4.13 for  guidelines.  
k. Long term follow up assessments (examination, non -thyroid laboratories,  adverse event/late 
toxicity assessments) should occur every [ADDRESS_912398] with endoscopy. Endoscopy is not required for oral cavity 
carcinoma. Endoscopy for oropharyngeal carcinoma may be performed as clinically indica ted. 
Endoscopy is required for hypopharyngeal and laryngeal  carcinoma.  
o. Cisplatin should be administered on Monday, Tuesday, or Wednesday of each treatment week 
and may be given either before or after the radiation therapy fraction that is given on the same  day. When 
cisplatin and pembrolizumab are administered on the same day in Arm 2, pembrolizumab should follow 
cisplatin.  
p. Thyroid auto -immunity will be monitored as specified in section  8.2. 
91 
 APPENDIX D: CTCAE v.4.0  
 
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 -06-14_QuickReference_5x7.pdf  
92 
 APPENDIX E: MEDWATCH FORM 3500A  
 
http://www.fda.gov/downloads/Safety/MedWatch/HowToReport/DownloadForms/ucm082728.pdf  
93 
 16. REFERENCES  
1. Kamangar F, Dores GM, Anderson WF. Patterns of Cancer Incidence, Mortality, and 
Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in  Different 
Geographic Regions of the World. Journal of Clinical Oncology  2006;24:[ADDRESS_912399] E. Cancer statistics, 2010. CA: a cancer journ al for 
clinicians  2010;60:277 -300. 
3. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer.  Lancet 
2008;371:[ADDRESS_912400] 
radiation therapy and two schedules of conc urrent chemoradiotherapy in patients with 
unresectable squamous cell head and neck cancer. Journal of clinical oncology : official  journal 
of the American Society of Clinical Oncology  2003;21:[ADDRESS_912401] E, Bourhis J, Group M -NC. Meta -analysis of 
chemotherapy in head and neck cancer (MACH -NC): an update on 93 randomised trials and 
17,346 patients. Radiotherapy and oncology : journal of the European Society for  Therapeutic 
Radiology and Oncology  2009;92:4 -14. 
6. Ang KK, Harris J, Wheeler R, et al. Human papi[INVESTIGATOR_306410]. The New England journal of medicine  2010;363:24 -35. 
7. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without 
concurren t chemotherapy for locally advanced head and neck cancer. The New England  journal 
of medicine  1998;338:1798 -804. 
8. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or  with 
docetaxel in head and neck cancer. The New England journal of medicine  2007;357:1705 -15. 
9. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for  squamous -cell 
carcinoma of the head and neck. The New England journal of medicine  2006;354:567 -78. 
10. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Inci dence trends for  human 
papi[INVESTIGATOR_28597] -related and -unrelated oral squamous cell carcinomas in the [LOCATION_002]. 
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 
2008;26:612 -9. 
11. O'Sullivan B, Huang SH, Perez -Ordon ez B, et al. Outcomes of HPV -related 
oropharyngeal cancer patients treated by [CONTACT_315662]. 
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology  and 
Oncology  2012;103:49 -56. 
12. Marur S, Li S, Cmelak A, et al. E 1308: A phase II trial of induction chemotherapy 
followed by [CONTACT_675088][INVESTIGATOR_27509] -associated resectable squamous cell carcinoma of the oropharynx. J Clin Oncol 
(suppl; a bstr 6005)  2013.  
13. Seiwert TY, Burtness B, Weiss J, et al. A phase Ib study of MK -3475 in patients with 
human papi[INVESTIGATOR_28597] (HPV) -associated and non -HPV –associated head and neck (H/N) cancer. 
Journal of clinical oncology : official journal of the American S ociety of Clinical Oncology  2014 
(suppl; abstr  6011);32:5s.  
14. Disis ML. Immune regulation of cancer. Journal of clinical oncology : official journal  of 
the American Society of Clinical Oncology  2010;28:[ADDRESS_912402], et al. Tumor -associated B7 -H1 promotes  T-cell 
apoptosis: a potential mechanism of immune evasion. Nature medicine  2002;8:793 -800. 
94 
 16. Sharpe AH, Freeman GJ. The B7 -CD28 superfamily. Nature reviews Immunology 
2002;2:116 -26. 
17. Brown JA, Dorfman DM, Ma FR, e t al. Blockade of programmed death -1 ligands on 
dendritic cells enhances T cell activation and cytokine production. Journal of immunology 
2003;170:[ADDRESS_912403] in tolerance and  autoimmunity. 
Immunological revi ews 2010;236:219 -42. 
19. Thompson RH, Dong H, Lohse CM, et al. PD -1 is expressed by [CONTACT_20150] -infiltrating 
immune cells and is associated with poor outcome for patients with renal cell carcinoma.  Clinical 
cancer research : an official journal of the American Assoc iation for Cancer Research 
2007;13:1757 -61. 
20. Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll  or 
Hyde. Cancer metastasis reviews  2007;26:373 -400. 
21. Usubutun A, Ayhan A, Uygur MC, Ozen H, Toklu C, Ruacan S. Prognostic factors  in 
renal cell carcinoma. Journal of experimental & clinical cancer research : CR  1998;17:[ADDRESS_912404] of epi[INVESTIGATOR_199920] -small cell lung cancer. Clinical 
cancer research : an official journal of the American Association for Cancer Research 
2008;14:5220 -7. 
23. Deschoolmeester V, Baay M, Van Marck E, et al. Tumor infiltrating lymphocytes: an 
intriguing player in the survival of colorectal cancer patients. BMC immunology  2010;11:19.  
24. Diez M, Pollan M, Enriquez JM, et al. Histopathologic prognostic score in  colorectal 
adenocarcinomas. Anticancer research  1998;18:[ADDRESS_912405] clinical outcome. Science  2006;313:1960 -4. 
26. Hiraoka N. Tumor -infiltrating lymphocytes and hepatocellular carcinoma:  molecular 
biology. International journal of clinical oncology  2010;15:544 -51. 
27. Nobili C, Degrate L, Caprotti R, et al. Prolonged survival of a patient affected by 
[CONTACT_80099] -2 immunotherapy. Report of a case. Tumori  2008;94:426 -30. 
28. Hodi FS, Dranoff G. The biologic  importance of tumor -infiltrating lymphocytes. Journal 
of cutaneous pathology 2010;[ADDRESS_912406]  1:48-53. 
29. Kloor M. Lymphocyte infiltration and prognosis in colorectal cancer. The  Lancet 
Oncology  2009;10:840 -1. 
30. Hillen F, Baeten CI, van de Winkel A, et al. Leukoc yte infiltration and tumor  cell 
plasticity are parameters of aggressiveness in primary cutaneous melanoma. Cancer 
immunology, immunotherapy : CII  2008;57:97 -106. 
31. Lee HE, Chae SW, Lee YJ, et al. Prognostic implications of type and density of tumour - 
infiltrating lymphocytes in gastric cancer. British journal of cancer  2008;99:1704 -11. 
32. Leffers N, Gooden MJ, de Jong RA, et al. Prognostic significance of tumor -infiltrating T - 
lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.  Cancer 
immunology, immunotherapy : CII  2009;58:449 -59. 
33. Nishimura H, Honjo T, Minato N. Facilitation of beta selection and modification of 
positive selection in the thymus of PD -1-deficient mice. The Journal of experimental  medicine 
2000;191:891 -8. 
95 
 34. Liotta F, Gacci M, Frosali F, et al. Frequency of regulatory T cells in peripheral blood 
and in tumour -infiltrating lymphocytes correlates with poor prognosis in renal cell  carcinoma. 
BJU international  2011;107:1500 -6. 
35. Cooper JS, Pajak TF, F orastiere AA, et al. Postoperative concurrent radiotherapy and 
chemotherapy for high -risk squamous -cell carcinoma of the head and neck. The New  England 
journal of medicine  2004;350:1937 -44. 
36. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without 
concomitant chemotherapy for locally advanced head and neck cancer. The New England  journal 
of medicine  2004;350:1945 -52. 
37. Niedernhofer LJ, Garinis GA, Raams A, et al. A new progeroid syndrome reveals  that 
genotoxic stress suppresses the som atotroph axis. Nature  2006;444:1038 -43. 
38. Palom Y, Suresh Kumar G, Tang LQ, et al. Relative toxicities of DNA cross -links and 
monoadducts: new insights from studies of decarbamoyl mitomycin C and mitomycin C. 
Chemical research in toxicology  2002;15:1398 -406. 
39. Henk JM. Controlled trials of synchronous chemotherapy with radiotherapy in head  and 
neck cancer: overview of radiation morbidity. Clinical oncology  1997;9:308 -12. 
40. Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and  associated 
outcomes in patients with head and neck cancer receiving radiotherapy with or without 
chemotherapy: a systematic literature review. Radiotherapy and oncology : journal of the 
European Society for Therapeutic Radiology and Oncology  2003;66:253 -62. 
41. Vermorken  JB, Kapteijn TS, Hart AA, Pi[INVESTIGATOR_535691]. Ototoxicity of cis - 
diamminedichloroplatinum (II): influence of dose, schedule and mode of  administration. 
European journal of cancer & clinical oncology  1983;19:53 -8. 
42. Chan AT, Leung SF, Ngan RK, et al. Overall surviva l after concurrent cisplatin - 
radiotherapy compared with radiotherapy alone in locoregionally advanced  nasopharyngeal 
carcinoma. Journal of the National Cancer Institute  2005;97:536 -9. 
43. Chiu TJ, Chen CH, Chien CY, Li SH, Tsai HT, Chen YJ. High ERCC1 express ion 
predicts cisplatin -based chemotherapy resistance and poor outcome in unresectable  squamous 
cell carcinoma of head and neck in a betel -chewing area. Journal of translational medicine 
2011;9:31.  
44. Jeremic B, Milicic B, Dagovic A, Vaskovic Z, Tadic L. Radia tion therapy with or 
without concurrent low -dose daily chemotherapy in locally advanced, nonmetastatic  squamous 
cell carcinoma of the head and neck. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology  2004;22:3540 -8. 
45. Quon H, Leong T, Haselow R, Leipzig B, Cooper J, Forastiere A. Phase III study of 
radiation therapy with or without cis -platinum in patients with unresectable squamous or 
undifferentiated carcinoma of the head and neck: an intergroup trial of the Eastern  Cooperative 
Oncology Group (E2382). International journal of radiation oncology, biology, physics 
2011;81:719 -25. 
46. Allen C, Duffy S, Teknos T, et al. Nuclear factor -kappaB -related serum factors as 
longitudinal biomarkers of response and survival in advance d oropharyngeal carcinoma.  Clinical 
cancer research : an official journal of the American Association for Cancer Research 
2007;13:3182 -90. 
47. Leibowitz MS, Andrade Filho PA, Ferrone S, Ferris RL. Deficiency of activated  STAT1 
in head and neck cancer cells mediates TAP1 -dependent escape from cytotoxic T lymphocytes. 
Cancer immunology, immunotherapy : CII  2011;60:[ADDRESS_912407] B, Ferris RL, Gooding W, Whiteside TL. Decreased absolute counts of 
T lymphocyte subsets and their relation t o disease in squamous cell carcinoma of the head and 
neck. Clinical cancer research : an official journal of the American Association for Cancer 
Research  2004;10:3755 -62. 
49. Whiteside TL. Immunobiology of head and neck cancer. Cancer metastasis  reviews 
2005;24:95 -105. 
50. Hoffmann TK, Dworacki G, Tsukihiro T, et al. Spontaneous apoptosis of circulating T 
lymphocytes in patients with head and neck cancer and its clinical importance. Clinical cancer 
research : an official journal of the American Association fo r Cancer Research  2002;8:2553 -62. 
51. Dasgupta S, Bhattacharya -Chatterjee M, O'Malley BW, Jr., Chatterjee SK. Inhibition of 
NK cell activity through TGF -beta 1 by [CONTACT_100276] -regulation of NKG2D in a murine model of  head 
and neck cancer. Journal of immunology  2005;17 5:5541 -50. 
52. Bauernhofer T, Kuss I, Henderson B, Baum AS, Whiteside TL. Preferential apoptosis  of 
CD56dim natural killer cell subset in patients with cancer. European journal of immunology 
2003;33:119 -24. 
53. Young MR, Wright MA, Lozano Y, Matthews JP, Benefield  J, Prechel MM.  Mechanisms 
of immune suppression in patients with head and neck cancer: influence on the immune infiltrate 
of the cancer. Int J Cancer  1996;67:333 -8. 
54. Baruah P, Lee M, Odutoye T, et al. Decreased levels of alternative co -stimulatory 
receptor s OX40 and 4 -1BB characterise T cells from head and neck cancer patients. 
Immunobiology  2012;217:669 -75. 
55. Lopez -Albaitero A, Nayak JV, Ogino T, et al. Role of antigen -processing machinery  in 
the in vitro resistance of squamous cell carcinoma of the head and  neck cells to recognition by 
[CONTACT_125614]. Journal of immunology  2006;176:3402 -9. 
56. Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects  in 
antigen -processing machinery in head and neck cancer. Clinical cancer research : an official 
journal of the American Association for Cancer Research  2006;12:3890 -5. 
57. Badoual C, Hans S, Merillon N, et al. PD -1-expressing tumor -infiltrating T cells are a 
favorable prognostic biomarker in HPV -associated head and neck cancer. Cancer research 
2013;73:[ADDRESS_912408] cancer. British journal of cancer  2013;108:1560 -5. 
59. Cho YA, Yoon HJ, Lee JI, Hong SP, Hong SD. Relationship between the expressions of 
PD-L1 and tumo r-infiltrating lymphocytes in oral squamous cell carcinoma. Oral oncology 
2011;47:[ADDRESS_912409] -Pi[INVESTIGATOR_2531] S, Peng S, Young GD, et al. Evidence for a Role of the PD -1:PD -L1 
Pathway in Immune Resistance of HPV -Associated Head and Neck Squamous Cell  Carcinoma. 
Cancer research  2013;73:1733 -41. 
61. Hodge JW, Guha C, Neefjes J, Gulley JL. Synergizing radiation therapy and 
immunotherapy for curing incurable cancers. Opportunities and challenges.  Oncology 
2008;22:1064 -70; discussion 75, 80 -1, 84. 
62. Deng L, Liang H, Burnette  B, et al. Irradiation and anti -PD-L1 treatment synergistically 
promote antitumor immunity in mice. The Journal of clinical investigation  2014;124:687 -95. 
63. Peters LJ, Weber RS, Morrison WH, By[CONTACT_352113], Garden AS, Goepfert H. Neck surgery  in 
patients with prim ary oropharyngeal cancer treated by [CONTACT_114658]. Head & neck 1996;18:552 - 
9. 
97 
 64. Velazquez RA, McGuff HS, Sycamore D, Miller FR. The role of computed tomographic 
scans in the management of the N -positive neck in head and neck squamous cell carcinoma  after 
chemoradiotherapy. Archives of otolaryngology --head & neck surgery  2004;130:[ADDRESS_912410] -RT neck dissection in patients with cervical 
metastatic disease from squamous cell carcinoma. International journal of radiation oncology, 
biology, physics  2002;52:420 -8. 
66. Moeller BJ, Rana V, Cannon BA, et al. Prospective risk -adjusted 
[18F]Fluorodeoxyglucose positron emission t omography and computed tomography  assessment 
of radiation response in head and neck cancer. Journal of clinical oncology : official journal of 
the American Society of Clinical Oncology  2009;27:2509 -15. 
67. Brkovich VS, Miller FR, Karnad AB, Hussey DH, McGuff H S, Otto RA. The role of 
positron emission tomography scans in the management of the N -positive neck in head and  neck 
squamous cell carcinoma after chemoradiotherapy. The Laryngoscope  2006;116:855 -8. 
68. Porceddu SV, Pryor DI, Burmeister E, et al. Results of a prospective study of  positron 
emission tomography -directed management of residual nodal abnormalities in node -positive 
head and neck cancer after definitive radiotherapy with or without systemic therapy. Head & 
neck  2011;33:1675 -82. 
69. Zimmer LA, Snyderman C,  Fukui MB, et al. The use of combined PET/CT for  localizing 
recurrent head and neck cancer: the Pi[INVESTIGATOR_675055]. Ear, nose, & throat journal 
2005;84:104, 6,  8-10. 
70. Passero VA, Branstetter BF, Shuai Y, et al. Response assessment by [CONTACT_675089] -CT 
scan versus CT scan alone using RECIST in patients with locally advanced head and neck  cancer 
treated with chemoradiotherapy. Annals of oncology : official journal of the European Society 
for Medical Oncology / ESMO  2010;21:2278 -83. 
71. Branstetter BFt, Blodgett T M, Zimmer LA, et al. Head and neck malignancy: is  PET/CT 
more accurate than PET or CT alone? Radiology  2005;235:580 -6. 
72. Zhang I, Branstetter BFt, Beswick DM, Maxwell JH, Gooding WE, Ferris RL.  The 
benefit of early PET/CT surveillance in HPV -associated head and neck squamous cell 
carcinoma. Archives of otolaryngology --head & neck surgery  2011;137:1106 -11. 
73. Postow MA, Callahan MK, Wolchok JD. The antitumor immunity of ipi[INVESTIGATOR_125]: (T - 
cell) memories to last a lifetime? Clinical cancer research : an official jour nal of the  American 
Association for Cancer Research  2012;18:1821 -3. 
74. Jie HB, Gildener -Leapman N, Li J, et al. Intratumoral regulatory T cells upregulate 
immunosuppressive molecules in head and neck cancer patients. British journal of cancer 
2013;109:[ADDRESS_912411] virally infected squamous cell carcinoma of the head and neck. Cancer 
research  2005;65:[ZIP_CODE] -55. 
76. Jie HB, Schuler PJ, Lee SC, et al. CTLA -4+ Re gulatory T Cells are Increased in 
Cetuximab Treated Head and Neck Cancer Patients, Suppress NK Cell Cytotoxicity  and 
Correlate with Poor Prognosis. Cancer research  2015.  
77. Cancer Genome Atlas N. Comprehensive genomic characterization of head and  neck 
squamou s cell carcinomas. Nature  2015;517:576 -82. 
78. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape 
determines sensitivity to PD -1 blockade in non -small cell lung cancer. Science  2015;348:124 -8. 
98 
 79. Snyder A, Wolchok JD, Ch an TA. Genetic basis for clinical response to CTLA -4 
blockade. The New England journal of medicine  2015;372:783.  
 
